

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Drug Therapies for the Management of Sickle Cell... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/9-592/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/9-592" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Drug Therapies for the Management of Sickle Cell Disease" />
    
            <meta name="og:title" content="F1000Research Article: Drug Therapies for the Management of Sickle Cell Disease.">
            <meta name="og:description" content="Read the latest article version by Parul Rai, Kenneth I. Ataga, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="24752">
            <meta name="article-id" content="22433">
            <meta name="dc.title" content="Drug Therapies for the Management of Sickle Cell Disease">
            <meta name="dc.description" content="Sickle cell disease (SCD) afflicts millions of people worldwide but is referred to as an orphan disease in the United States. Over the past several decades, there has been an increasing understanding of the pathophysiology of SCD and its complications. While most individuals with SCD in resource-rich countries survive into adulthood, the life expectancy of patients with SCD remains substantially shorter than for the general African-American population. SCD can be cured using hematopoietic stem cell transplantation and possibly gene therapy, but these treatment approaches are not available to most patients, the majority of whom reside in low- and middle-income countries. Until relatively recently, only one drug, hydroxyurea, was approved by the US Food and Drug Administration to ameliorate disease severity. Multiple other drugs (L-glutamine, crizanlizumab, and voxelotor) have recently been approved for the treatment of SCD, with several others at various stages of clinical testing. The availability of multiple agents to treat SCD raises questions related to the choice of appropriate drug therapy, combination of multiple agents, and affordability of recently approved products. The enthusiasm for new drug development provides opportunities to involve patients in low- and middle-income nations in the testing of potentially disease-modifying therapies and has the potential to contribute to capacity building in these environments. Demonstration that these agents, alone or in combination, can prevent or decrease end-organ damage would provide additional evidence for the role of drug therapies in improving outcomes in SCD.">
            <meta name="dc.subject" content="Sickle cell disease, Treatment, Novel Drugs, Drug Development, Clinical Trials">
            <meta name="dc.creator" content="Rai, Parul">
            <meta name="dc.creator" content="Ataga, Kenneth I.">
            <meta name="dc.date" content="2020/06/11">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.22433.1">
            <meta name="dc.source" content="F1000Research 2020 9:592">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Sickle cell disease">
            <meta name="prism.keyword" content="Treatment">
            <meta name="prism.keyword" content="Novel Drugs">
            <meta name="prism.keyword" content="Drug Development">
            <meta name="prism.keyword" content="Clinical Trials">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2020/06/11">
            <meta name="prism.volume" content="9">
            <meta name="prism.number" content="592">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.22433.1">
            <meta name="prism.url" content="https://f1000research.com/articles/9-592">
            <meta name="citation_title" content="Drug Therapies for the Management of Sickle Cell Disease">
            <meta name="citation_abstract" content="Sickle cell disease (SCD) afflicts millions of people worldwide but is referred to as an orphan disease in the United States. Over the past several decades, there has been an increasing understanding of the pathophysiology of SCD and its complications. While most individuals with SCD in resource-rich countries survive into adulthood, the life expectancy of patients with SCD remains substantially shorter than for the general African-American population. SCD can be cured using hematopoietic stem cell transplantation and possibly gene therapy, but these treatment approaches are not available to most patients, the majority of whom reside in low- and middle-income countries. Until relatively recently, only one drug, hydroxyurea, was approved by the US Food and Drug Administration to ameliorate disease severity. Multiple other drugs (L-glutamine, crizanlizumab, and voxelotor) have recently been approved for the treatment of SCD, with several others at various stages of clinical testing. The availability of multiple agents to treat SCD raises questions related to the choice of appropriate drug therapy, combination of multiple agents, and affordability of recently approved products. The enthusiasm for new drug development provides opportunities to involve patients in low- and middle-income nations in the testing of potentially disease-modifying therapies and has the potential to contribute to capacity building in these environments. Demonstration that these agents, alone or in combination, can prevent or decrease end-organ damage would provide additional evidence for the role of drug therapies in improving outcomes in SCD.">
            <meta name="citation_description" content="Sickle cell disease (SCD) afflicts millions of people worldwide but is referred to as an orphan disease in the United States. Over the past several decades, there has been an increasing understanding of the pathophysiology of SCD and its complications. While most individuals with SCD in resource-rich countries survive into adulthood, the life expectancy of patients with SCD remains substantially shorter than for the general African-American population. SCD can be cured using hematopoietic stem cell transplantation and possibly gene therapy, but these treatment approaches are not available to most patients, the majority of whom reside in low- and middle-income countries. Until relatively recently, only one drug, hydroxyurea, was approved by the US Food and Drug Administration to ameliorate disease severity. Multiple other drugs (L-glutamine, crizanlizumab, and voxelotor) have recently been approved for the treatment of SCD, with several others at various stages of clinical testing. The availability of multiple agents to treat SCD raises questions related to the choice of appropriate drug therapy, combination of multiple agents, and affordability of recently approved products. The enthusiasm for new drug development provides opportunities to involve patients in low- and middle-income nations in the testing of potentially disease-modifying therapies and has the potential to contribute to capacity building in these environments. Demonstration that these agents, alone or in combination, can prevent or decrease end-organ damage would provide additional evidence for the role of drug therapies in improving outcomes in SCD.">
            <meta name="citation_keywords" content="Sickle cell disease, Treatment, Novel Drugs, Drug Development, Clinical Trials">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Parul Rai">
            <meta name="citation_author_institution" content="Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA">
            <meta name="citation_author" content="Kenneth I. Ataga">
            <meta name="citation_author_institution" content="Center for Sickle Cell Disease, University of Tennessee Health Science Center, Memphis, TN, USA">
            <meta name="citation_publication_date" content="2020/06/11">
            <meta name="citation_volume" content="9">
            <meta name="citation_publication_number" content="592">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.22433.1">
            <meta name="citation_firstpage" content="592">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/9-592/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/9-592.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=24752 /> <input type=hidden id=articleId name=articleId value=22433 /> <input type=hidden id=xmlUrl value="/articles/9-592/v1/xml"/> <input type=hidden id=xmlFileName value="-9-592-v1.xml"> <input type=hidden id=article_uuid value=425cc9df-2d8a-413e-8906-cd62ac08d2a8 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Drug Therapies for the Management of Sickle Cell Disease"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.22433.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.22433.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/9-592"
  },
  "headline": "Drug Therapies for the Management of Sickle Cell Disease",
  "datePublished": "2020-06-11T15:31:27",
  "dateModified": "2020-06-11T15:31:27",
  "author": [
    {
      "@type": "Person",
      "name": "Parul Rai"
    },    {
      "@type": "Person",
      "name": "Kenneth I. Ataga"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Sickle cell disease (SCD) afflicts millions of people worldwide but is referred to as an orphan disease in the United States. Over the past several decades, there has been an increasing understanding of the pathophysiology of SCD and its complications. While most individuals with SCD in resource-rich countries survive into adulthood, the life expectancy of patients with SCD remains substantially shorter than for the general African-American population. SCD can be cured using hematopoietic stem cell transplantation and possibly gene therapy, but these treatment approaches are not available to most patients, the majority of whom reside in low- and middle-income countries. Until relatively recently, only one drug, hydroxyurea, was approved by the US Food and Drug Administration to ameliorate disease severity. Multiple other drugs (L-glutamine, crizanlizumab, and voxelotor) have recently been approved for the treatment of SCD, with several others at various stages of clinical testing. The availability of multiple agents to treat SCD raises questions related to the choice of appropriate drug therapy, combination of multiple agents, and affordability of recently approved products. The enthusiasm for new drug development provides opportunities to involve patients in low- and middle-income nations in the testing of potentially disease-modifying therapies and has the potential to contribute to capacity building in these environments. Demonstration that these agents, alone or in combination, can prevent or decrease end-organ damage would provide additional evidence for the role of drug therapies in improving outcomes in SCD."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/9-592/v1",
            "name": "Drug Therapies for the Management of Sickle Cell Disease"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Drug Therapies for the Management of Sickle Cell Disease </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=24752 data-id=22433 data-downloads="" data-views="" data-scholar="10.12688/f1000research.22433.1" data-recommended="" data-doi="10.12688/f1000research.22433.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/9-592/v1/pdf?article_uuid=425cc9df-2d8a-413e-8906-cd62ac08d2a8" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-22433-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-22433-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-22433-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Rai P and Ataga KI. Drug Therapies for the Management of Sickle Cell Disease [version 1; peer review: 1 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):592 (<a class=new-orange href="https://doi.org/10.12688/f1000research.22433.1" target=_blank>https://doi.org/10.12688/f1000research.22433.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-22433-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=22433 id=track-article-signin-22433 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/22433?target=/articles/9-592/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=24752 /> <input name=articleId type=hidden value=22433 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Drug Therapies for the Management of Sickle Cell Disease</h1><span class=other-info> [version 1; peer review: 1 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Parul Rai<a href="https://orcid.org/0000-0002-5770-7280" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-5770-7280</div><sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:kataga@uthsc.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Kenneth I. Ataga</span></a><a href="https://orcid.org/0000-0002-4501-9982" target=_blank id=author-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-4501-9982</div><sup>2</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Parul Rai<a href="http://orcid.org/0000-0002-5770-7280" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-5770-7280</div><sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:kataga@uthsc.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Kenneth I. Ataga</span></a><a href="http://orcid.org/0000-0002-4501-9982" target=_blank id=mauthor-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-4501-9982</div><sup>2</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 11 Jun 2020 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.22433.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA<br/> <sup>2</sup> Center for Sickle Cell Disease, University of Tennessee Health Science Center, Memphis, TN, USA<br/> <p> <div class=margin-bottom> Parul Rai <br/> <span>Roles: </span> Investigation, Writing – Original Draft Preparation </div> <div class=margin-bottom> Kenneth I. Ataga <br/> <span>Roles: </span> Conceptualization, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=69027-64620></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=69028-64619></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Sickle cell disease (SCD) afflicts millions of people worldwide but is referred to as an orphan disease in the United States. Over the past several decades, there has been an increasing understanding of the pathophysiology of SCD and its complications. While most individuals with SCD in resource-rich countries survive into adulthood, the life expectancy of patients with SCD remains substantially shorter than for the general African-American population. SCD can be cured using hematopoietic stem cell transplantation and possibly gene therapy, but these treatment approaches are not available to most patients, the majority of whom reside in low- and middle-income countries. Until relatively recently, only one drug, hydroxyurea, was approved by the US Food and Drug Administration to ameliorate disease severity. Multiple other drugs (L-glutamine, crizanlizumab, and voxelotor) have recently been approved for the treatment of SCD, with several others at various stages of clinical testing. The availability of multiple agents to treat SCD raises questions related to the choice of appropriate drug therapy, combination of multiple agents, and affordability of recently approved products. The enthusiasm for new drug development provides opportunities to involve patients in low- and middle-income nations in the testing of potentially disease-modifying therapies and has the potential to contribute to capacity building in these environments. Demonstration that these agents, alone or in combination, can prevent or decrease end-organ damage would provide additional evidence for the role of drug therapies in improving outcomes in SCD. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Sickle cell disease, Treatment, Novel Drugs, Drug Development, Clinical Trials </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Kenneth I. Ataga (<a href="mailto:kataga@uthsc.edu">kataga@uthsc.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Kenneth I. Ataga </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> KIA has served on clinical advisory boards and/or served as a consultant for Global Blood Therapeutics, Novartis, Emmaus Life Sciences, Editas Medicine, and Novo Nordisk. PR has no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> This work is supported by an award from the US Food and Drug Administration - R01FD006030 (KIA). <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2020 Rai P and Ataga KI. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Rai P and Ataga KI. Drug Therapies for the Management of Sickle Cell Disease [version 1; peer review: 1 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):592 (<a href="https://doi.org/10.12688/f1000research.22433.1" target=_blank>https://doi.org/10.12688/f1000research.22433.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 11 Jun 2020, <b>9</b>(F1000 Faculty Rev):592 (<a href="https://doi.org/10.12688/f1000research.22433.1" target=_blank>https://doi.org/10.12688/f1000research.22433.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 11 Jun 2020, <b>9</b>(F1000 Faculty Rev):592 (<a href="https://doi.org/10.12688/f1000research.22433.1" target=_blank>https://doi.org/10.12688/f1000research.22433.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d25416e148>Introduction</h2><p class="" id=d25416e151>Although referred to as an orphan disease in the United States (US), sickle cell disease (SCD) affects millions of individuals worldwide, with the vast majority residing in sub-Saharan Africa and India<sup><a href="#ref-1">1</a></sup>. SCD is characterized by the presence of sickle hemoglobin (HbS), hemolytic anemia, vaso-occlusive complications, and cumulative end-organ damage. The mortality rate associated with SCD in sub-Saharan Africa remains high, with an estimated 50 to 90% of children dying before the age of 5<sup><a href="#ref-2">2</a></sup>. However, the majority of children with SCD in resource-rich countries live to adulthood<sup><a href="#ref-3">3</a>–<a href="#ref-5">5</a></sup>. Despite increased survival to adulthood, individuals with SCD in resource-rich nations continue to have a shorter life expectancy than the general population<sup><a href="#ref-6">6</a>–<a href="#ref-9">9</a></sup>. There has been substantial progress with the use of allogeneic bone marrow transplantation as a curative therapy in SCD, and increasing evidence supports the curative potential of gene therapy and gene editing<sup><a href="#ref-10">10</a>,<a href="#ref-11">11</a></sup>. However, as these modalities are not available to the vast majority of patients, most of whom reside in resource-limited countries, the availability of drug therapies that are safe, effective, and affordable remains highly desirable.</p><p class="" id=d25416e183>This review will focus on approaches to develop drug therapies in SCD, ongoing and recently completed trials, and our perspective on the use of approved drugs.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d25416e189>Pathophysiology</h2><p class="" id=d25416e192>The development of effective therapies for SCD depends on an adequate understanding of its pathophysiology. Although the pathophysiology of SCD is complex and involves multiple pathways, the primary event is due to the polymerization of HbS following deoxygenation<sup><a href="#ref-12">12</a></sup>. The rate and extent of polymer formation depends on the degree and duration of HbS deoxygenation, presence of fetal hemoglobin (HbF), and the intracellular concentration of HbS. Clinical manifestations of SCD appear to be driven by two major pathophysiological processes: vaso-occlusion with ischemia-reperfusion injury and hemolytic anemia<sup><a href="#ref-13">13</a></sup>. Vaso-occlusion occurs because of adhesive interactions of leukocytes and sickle RBCs with the endothelium causing microvascular obstruction and subsequent tissue ischemia<sup><a href="#ref-13">13</a></sup>. These episodes of vascular obstruction are followed by the restoration of blood flow, which promotes further tissue injury by reperfusion. The inflammatory cascade resulting from ischemia-reperfusion is amplified by the activation of CD1d-restricted invariant natural killer T (iNKT) cells<sup><a href="#ref-14">14</a></sup>. The release of free plasma hemoglobin following intravascular hemolysis results in direct scavenging of nitric oxide (NO), as well as the generation of reactive oxygen species, powerful scavengers of NO<sup><a href="#ref-15">15</a>,<a href="#ref-16">16</a></sup>. NO is usually produced by the endothelium and regulates basal vasodilator tone as well as inhibits the activation of platelets and the coagulation system and the transcriptional expression of nuclear factor κB (NFκB)-dependent adhesion molecules, such as vascular cell-adhesion molecule-1, intercellular cell-adhesion molecule-1, and selectins<sup><a href="#ref-17">17</a>,<a href="#ref-18">18</a></sup>. HbS polymerization as well as its multiple downstream consequences, including endothelial cell injury, endothelial dysfunction, increased oxidant stress, inflammation, and coagulation and platelet activation, are therapeutic targets in SCD (<a href="#f1">Figure 1</a>). SCD has been dichotomized into two overlapping sub-phenotypes: viscosity-vaso-occlusion (higher hemoglobin levels, possibly increased blood viscosity, and complications such as osteonecrosis, acute chest syndrome, and acute pain crisis) and hemolysis-endothelial dysfunction (increased hemolysis with lower hemoglobin levels and higher levels of hemolytic markers, including reticulocyte count and serum lactate dehydrogenase, and complications such as leg ulcers, priapism, stroke, and possibly pulmonary hypertension)<sup><a href="#ref-19">19</a></sup>. While somewhat simplistic, this classification is useful to understand the pathobiology of disease complications and may provide guidance on the effects of therapies on disease-related complications. The pathophysiology of SCD has been reviewed more extensively elsewhere<sup><a href="#ref-20">20</a>–<a href="#ref-22">22</a></sup>.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/24752/7339a6ba-6ba0-4c0f-99e7-49682be38706_figure1.gif"><img alt="7339a6ba-6ba0-4c0f-99e7-49682be38706_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/24752/7339a6ba-6ba0-4c0f-99e7-49682be38706_figure1.gif"></a><div class=caption><h3>Figure 1. Potential targets of pharmacologic agents in sickle cell disease</h3><p id=d25416e250>HbF, hemoglobin F; NKT, natural killer T-cells; NO, nitric oxide; RBCs, red blood cells. Adapted with permission from Ataga KI and Stocker J. <i>Br J Haematol</i>, 2015.</p></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d25416e263>Drug therapies for sickle cell disease</h2><p class="" id=d25416e266>Despite an improved understanding of the pathophysiology of SCD, available drug treatments remain limited. For many years, hydroxyurea was the only drug available to modify the severity of SCD<sup><a href="#ref-23">23</a></sup>. However, there has been progress in the development of drug therapies with recent approvals of L-glutamine, crizanlizumab, and voxelotor by the US Food and Drug Administration (FDA)<sup><a href="#ref-24">24</a>–<a href="#ref-26">26</a></sup>. Based on our current understanding of SCD pathophysiology, there are multiple possible approaches to treating the disease and its complications, including inhibition of HbS polymerization and amelioration of multiple downstream sequelae of HbS polymerization.</p><div class=section><a name=d25416e280 class=n-a></a><h3 class=section-title>Inhibition of sickle hemoglobin polymerization</h3><p class="" id=d25416e285>Therapeutic approaches targeting HbS polymerization, including 1) blocking intermolecular contacts in the sickle fiber, 2) induction of HbF synthesis, 3) reduction of intracellular HbS concentration, 4) increase in oxygen affinity, and 5) reduction of the concentration of 2,3-diphosphoglycerate, have been described<sup><a href="#ref-27">27</a></sup>. <a href="#T1">Table 1</a> lists ongoing studies of anti-sickling agents in SCD.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Ongoing clinical trials of anti-sickling agents in sickle cell disease.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d25416e306 class=n-a></a><thead><a name=d25416e308 class=n-a></a><tr><a name=d25416e310 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e312 class=n-a></a>Mechanism</th><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e315 class=n-a></a>Drug</th><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e318 class=n-a></a>Sponsor</th><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e321 class=n-a></a>NCT number<br class=br>(study<br class=br>acronym)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e328 class=n-a></a>Clinical phase/status</th><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e332 class=n-a></a>Intervention</th><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e335 class=n-a></a>Number/age</th><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e338 class=n-a></a>Objective</th></tr></thead><tbody><a name=d25416e343 class=n-a></a><tr><a name=d25416e345 class=n-a></a><td align=left colspan=1 rowspan=3 valign=top><a name=d25416e347 class=n-a></a>HbF induction</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e350 class=n-a></a>Nicotinamide vs. THU<br class=br>and decitabine</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e355 class=n-a></a>EpiDestiny, Inc;<br class=br>NIH; NHLBI</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e360 class=n-a></a>NCT04055818</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e363 class=n-a></a>Phase I<br class=br>Recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e369 class=n-a></a>Oral nicotinamide vs. THU<br class=br>+ decitabine for 12 weeks<br class=br>followed by combination for<br class=br>a further 12 weeks</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e378 class=n-a></a>20/≥18 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e381 class=n-a></a>Compare effect of oral nicotinamide<br class=br>vs. THU-decitabine and in<br class=br>combination on hemoglobin level at<br class=br>week 12</td></tr><tr><a name=d25416e391 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e393 class=n-a></a>Panobinostat<br class=br>(LBH589)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e398 class=n-a></a>Abdullah Kutlar</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e401 class=n-a></a>NCT01245179</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e404 class=n-a></a>Phase I<br class=br>Active, not<br class=br>recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e411 class=n-a></a>Oral, for 12 weeks</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e415 class=n-a></a>18/≥18 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e418 class=n-a></a>Evaluate safety, HbF, F cells,<br class=br>total hemoglobin, markers of<br class=br>inflammation, QOL measures</td></tr><tr><a name=d25416e426 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e428 class=n-a></a>Metformin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e431 class=n-a></a>Baylor College of<br class=br>Medicine</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e436 class=n-a></a>NCT02981329<br class=br>(FITMet)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e441 class=n-a></a>Phase I<br class=br>Recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e446 class=n-a></a>Hydroxyurea + metformin<br class=br>vs. metformin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e452 class=n-a></a>56/10–60 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e455 class=n-a></a>Change in HbF or total hemoglobin,<br class=br>QOL, RNA sequencing</td></tr><tr><a name=d25416e461 class=n-a></a><td align=left colspan=1 rowspan=6 valign=top><a name=d25416e463 class=n-a></a>Allosteric<br class=br>modifier (to<br class=br>the R-state)</td><td align=left colspan=1 rowspan=6 valign=top><a name=d25416e470 class=n-a></a>Voxelotor (formerly<br class=br>GBT440)</td><td align=left colspan=1 rowspan=6 valign=top><a name=d25416e475 class=n-a></a>Global blood<br class=br>therapeutics</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e480 class=n-a></a>NCT03943615<br class=br>(expanded<br class=br>access)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e487 class=n-a></a>Approved for<br class=br>marketing</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e493 class=n-a></a>Oral</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e496 class=n-a></a>≥12 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e499 class=n-a></a>To provide early access to patients<br class=br>without alternative treatment options</td></tr><tr><a name=d25416e505 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e507 class=n-a></a>NCT04247594</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e510 class=n-a></a>Phase II<br class=br>Recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e515 class=n-a></a>Oral, open-label</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e518 class=n-a></a>45/18–60 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e521 class=n-a></a>Dose escalation study to evaluate<br class=br>safety and tolerability of doses,<br class=br>1,500 mg to 3,000 mg daily</td></tr><tr><a name=d25416e530 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e532 class=n-a></a>NCT02850406</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e535 class=n-a></a>Phase IIa<br class=br>Recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e540 class=n-a></a>Part A: single dose Part B:<br class=br>24 weeks<br class=br>Part C: 48 weeks</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e547 class=n-a></a>125/4–17 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e550 class=n-a></a>Pharmacokinetics, change in<br class=br>hemoglobin, effect on hemolysis,<br class=br>TCD velocity, safety</td></tr><tr><a name=d25416e558 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e560 class=n-a></a>NCT03573882</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e563 class=n-a></a>Phase III<br class=br>Active, not<br class=br>recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e570 class=n-a></a>Oral, daily</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e573 class=n-a></a>179/≥12 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e576 class=n-a></a>Open-label extension study,<br class=br>adverse events, frequency of SCD-<br class=br>related complications</td></tr><tr><a name=d25416e584 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e586 class=n-a></a>NCT04218084<br class=br>(HOPE kids 2)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e591 class=n-a></a>Phase III<br class=br>Not yet<br class=br>recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e598 class=n-a></a>Oral voxelotor vs. placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e601 class=n-a></a>224/2–14 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e604 class=n-a></a>Evaluate effect on TCD in children</td></tr><tr><a name=d25416e608 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e610 class=n-a></a>NCT04188509</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e613 class=n-a></a>Phase III<br class=br>Enrolling by<br class=br>invitation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e620 class=n-a></a>Oral, open-label</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e623 class=n-a></a>50/4–18 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e626 class=n-a></a>Evaluate safety and tolerability,<br class=br>SCD-related complications</td></tr><tr><a name=d25416e632 class=n-a></a><td align=left colspan=1 rowspan=2 valign=top><a name=d25416e634 class=n-a></a>Allosteric<br class=br>activator of<br class=br>RBC pyruvate<br class=br>kinase-R</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e643 class=n-a></a>AG-348 (Mitapivat<br class=br>sulfate)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e648 class=n-a></a>NHLBI</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e651 class=n-a></a>NCT04000165</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e654 class=n-a></a>Phase I<br class=br>Recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e660 class=n-a></a>Oral, with two dose<br class=br>escalations after 2 weeks</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e665 class=n-a></a>25/≥18 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e668 class=n-a></a>Safety and tolerability,<br class=br>pharmacokinetics, and<br class=br>pharmacodynamics</td></tr><tr><a name=d25416e676 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e678 class=n-a></a>FT-4202</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e681 class=n-a></a>Forma<br class=br>therapeutics</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e686 class=n-a></a>NCT03815695</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e689 class=n-a></a>Phase I<br class=br>Recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e694 class=n-a></a>Single and multiple<br class=br>ascending oral doses of<br class=br>FT-4202 vs. placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e702 class=n-a></a>130/12–60<br class=br>years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e707 class=n-a></a>Safety, pharmacokinetics,<br class=br>pharmacodynamics</td></tr><tr><a name=d25416e714 class=n-a></a><td align=left colspan=1 rowspan=2 valign=top><a name=d25416e716 class=n-a></a>RBC ion<br class=br>transport<br class=br>channels</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e723 class=n-a></a>SCD-101</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e726 class=n-a></a>Invenux</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e729 class=n-a></a>NCT02380079</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e732 class=n-a></a>Phase Ib<br class=br>Recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e738 class=n-a></a>Part A: open-label, dose-<br class=br>escalation study<br class=br>Part B: randomized,<br class=br>placebo-controlled, cross-<br class=br>over study</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e749 class=n-a></a>60/18–55 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e752 class=n-a></a>Safety, change in hemoglobin,<br class=br>markers of hemolysis, QOL<br class=br>measures, functional capacity</td></tr><tr><a name=d25416e760 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e762 class=n-a></a>Memantine<br class=br>(NMDAR antagonist)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e767 class=n-a></a>HaEmek<br class=br>Medical Center,<br class=br>Israel</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e774 class=n-a></a>NCT03247218</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e777 class=n-a></a>Phase IIa/b<br class=br>Recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e782 class=n-a></a>Oral, once daily for 1 year</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e786 class=n-a></a>40/≥10years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e789 class=n-a></a>Safety, frequency of<br class=br>hospitalizations, duration of<br class=br>hospitalizations, analgesic use,<br class=br>transfusion requirement, QOL<br class=br>measures</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d25416e805 class=n-a></a><p id=d25416e807> HbF, fetal hemoglobin; QOL, quality of life; NHLBI, National Heart, Lung, and Blood Institute; NMDAR, N-methyl-D-aspartate receptor; RBC, red blood cell; SCD, sickle cell disease; TCD, transcranial doppler; THU, tetrahydrouridine; VOC, vaso-occlusive crisis.</p></div></div></div><p class="" id=d25416e813><i><b>Induction of fetal hemoglobin.</b></i> High levels of HbF ameliorate the severity of SCD<sup><a href="#ref-8">8</a>,<a href="#ref-28">28</a>,<a href="#ref-29">29</a></sup>. Hydroxyurea strongly induces HbF<sup><a href="#ref-30">30</a></sup>, although the mechanisms by which it does so are still unclear<sup><a href="#ref-30">30</a>–<a href="#ref-33">33</a></sup>. Hydroxyurea improves erythrocyte deformability, lowers hemolysis, decreases circulating leukocytes and reticulocytes<sup><a href="#ref-34">34</a></sup>, reduces adhesion receptor expression<sup><a href="#ref-35">35</a>–<a href="#ref-38">38</a></sup>, and is an NO donor<sup><a href="#ref-39">39</a>,<a href="#ref-40">40</a></sup>. In two placebo-controlled, phase III trials, hydroxyurea significantly reduced the frequency of vaso-occlusive crises, acute chest syndrome, blood transfusion requirement, and hospitalizations in adults and children with SCD<sup><a href="#ref-23">23</a>,<a href="#ref-41">41</a></sup>. Treatment with low, fixed weight-based dosing of hydroxyurea (10 mg/kg daily) also decreased the frequency of SCD-related complications with low toxicity<sup><a href="#ref-42">42</a>,<a href="#ref-43">43</a></sup>. Hydroxyurea further ameliorates SCD morbidity by decreasing the risk of stroke and chronic kidney disease<sup><a href="#ref-44">44</a>,<a href="#ref-45">45</a></sup> and may reduce mortality in SCD<sup><a href="#ref-46">46</a>–<a href="#ref-49">49</a></sup>. Recent studies to optimize hydroxyurea therapy are exploring dose maximization via pharmacokinetics-based dosing<sup><a href="#ref-50">50</a>–<a href="#ref-54">54</a></sup>. Despite its multiple benefits, a substantial number of patients on hydroxyurea may not obtain an adequate clinical response.</p><p class="" id=d25416e894>Inhibitors of epigenetic enzymes which repress γ-globin genes, including DNA methyltransferase (DNMT1), histone deacetylases, and lysine-specific demethylase (LSD-1), and γ-globin gene co-activator agonists are being evaluated in SCD. Decitabine (5-aza-2’-deoxycytidine), a DNA hypomethylating agent which depletes DNMT1, increased HbF and total hemoglobin levels at non-cytotoxic doses in patients who had no responses to hydroxyurea<sup><a href="#ref-55">55</a></sup>. However, it has a very short plasma half-life and negligible oral bioavailability due to rapid inactivation by cytidine deaminase (CDA)<sup><a href="#ref-55">55</a></sup>. The combination of escalating doses of oral decitabine and an oral CDA inhibitor, tetrahydrouridine (THU), was well tolerated, and the highest tested dose increased HbF, doubled F-cells by approximately 80% of total RBCs, increased total hemoglobin, and decreased biomarkers of hemolysis, coagulation activation, and inflammation<sup><a href="#ref-56">56</a></sup>.</p><p class="" id=d25416e910>Histone deacetylase (HDAC) inhibitors increase HbF levels<sup><a href="#ref-57">57</a>–<a href="#ref-63">63</a></sup>. Although treatment with intermittent doses of sodium butyrate produced sustained increases in HbF, F-cells, and total hemoglobin<sup><a href="#ref-57">57</a></sup>, the orally available sodium dimethyl butyrate (HQK-1001) did not significantly increase HbF and appeared to result in more pain crisis compared with placebo<sup><a href="#ref-63">63</a></sup>. A phase II study of the global HDAC inhibitor vorinostat was terminated early owing to poor accrual. Selective HDAC1/2 inhibition with ACY-957 increased HbF <i>in vitro</i> and represents a promising therapeutic approach with a better safety profile<sup><a href="#ref-64">64</a></sup>. Based on the success of the LSD-1 inhibitors RN-1 and ORY-3001 in increasing HbF and F-cells in preclinical studies<sup><a href="#ref-65">65</a>–<a href="#ref-67">67</a></sup>, INCB059872 was investigated (NCT03132324). However, this phase I study was terminated early for business reasons. Pomalidomide, a third-generation immunomodulatory drug, produced modest increases of HbF, augmented erythropoiesis, and preserved bone marrow function following 8 weeks of treatment in transgenic sickle mice<sup><a href="#ref-68">68</a></sup>. Pomalidomide appeared to increase HbF and total hemoglobin only at the highest dose or with greater than 6 months of exposure<sup><a href="#ref-69">69</a></sup>. The safety and efficacy of increasing the expression of γ-globin gene co-activators—FOXO3 agonist<sup><a href="#ref-70">70</a></sup> (metformin [NCT02983129]), nuclear factor-like 2 (Nrf2) agonist<sup><a href="#ref-71">71</a></sup> (dimethyl fumarate), and SIRT1<sup><a href="#ref-72">72</a></sup>—to augment HbF levels are being explored.</p><p class="" id=d25416e963><i><b>Allosteric modification of sickle hemoglobin to its high-oxygen affinity R-state.</b></i> Voxelotor, recently approved under the FDA’s accelerated approval program, is an orally bioavailable small molecule which binds to α-globin chains of hemoglobin, increases hemoglobin oxygen afﬁnity, and stabilizes the oxyhemoglobin state<sup><a href="#ref-73">73</a></sup>. Early studies showed a reduction in markers of hemolysis, with a rapid rise in hemoglobin by day 15<sup><a href="#ref-74">74</a></sup>. This response was not accompanied by worsening tissue hypoxia, based on serum erythropoietin levels and change in oxygen consumption (VO<sub>2</sub> max), even in participants receiving daily doses of 1,000 mg for 28 days and 900 mg for at least 90 days. Furthermore, voxelotor has been shown to reduce blood viscosity <i>in vitro</i><sup><a href="#ref-75">75</a></sup>. In a multicenter, phase III study of patients 12 to 65 years of age, randomly assigned to once-daily oral voxelotor doses of 1,500 mg, 900 mg, or placebo, a significantly higher percentage of subjects on 1,500 mg had a hemoglobin response of 1.0 g/dL at 24 weeks compared with placebo<sup><a href="#ref-76">76</a></sup>. In addition, subjects on the 1,500 mg dose saw significant reductions in indirect bilirubin and reticulocyte counts from baseline. A dose-dependent increase in hemoglobin following treatment with voxelotor was not accompanied by an increase in pain crisis rate. As this trial was not enriched for subjects with frequent pain crises, appropriately designed studies of patients with frequent pain episodes are needed to determine the effect of voxelotor on reducing such crises. Open-label extension studies to assess the long-term effects of voxelotor are ongoing.</p><p class="" id=d25416e991>5-hydroxymethyl-2-furfural (5HMF, Aes-103) interacts allosterically with HbS, increasing oxygen affinity and decreasing HbS polymerization and RBC sickling during hypoxia. A phase I trial, with oral doses of up to 4,000 mg, showed no significant side effects<sup><a href="#ref-77">77</a></sup>, but a phase II trial was terminated early because of unblinding of drug groups (NCT01987908). FT-4202, a novel selective activator of RBC pyruvate kinase, decreases intracellular 2,3-diphosphoglycerate levels, with a resulting increase in hemoglobin–oxygen affinity. It demonstrated a favorable safety profile in healthy individuals<sup><a href="#ref-78">78</a></sup> and is being investigated in a phase I study in SCD (NCT03815695).</p><p class="" id=d25416e1002>The oxygen delivery therapeutic agents sanguinate (pegylated bovine carboxyhemoglobin) and MP4CO (pegylated human carboxyhemoglobin) are dual transfer agents which release carbon monoxide when delivering oxygen to hypoxic tissues. They stabilize HbS in its R-state and appear to exhibit anti-inflammatory and anti-apoptotic activity by induction of Nrf2 and heme oxygenase-1<sup><a href="#ref-79">79</a>,<a href="#ref-80">80</a></sup>. Sanguinate had an acceptable safety profile<sup><a href="#ref-81">81</a>,<a href="#ref-82">82</a></sup>. A phase II study evaluating its efficacy during acute pain crisis was recently completed (NCT02411708).</p><p class="" id=d25416e1019><i><b>Increase red blood cell hydration.</b></i> The inverse relationship between HbS concentration and delay time suggests that even small decreases in intracellular HbS might be beneficial<sup><a href="#ref-83">83</a></sup>. Senicapoc selectively blocks the calcium-activated, potassium efflux (Gardos) channel and improves anemia and hemolysis in SCD<sup><a href="#ref-84">84</a>,<a href="#ref-85">85</a></sup>. Despite improvements in anemia and hemolysis, a phase III trial showed no significant decrease in the rate of pain crises compared to placebo<sup><a href="#ref-84">84</a></sup>. Similarly, studies of agents that block the potassium-chloride co-transport channel showed no clinical benefits<sup><a href="#ref-86">86</a>–<a href="#ref-88">88</a></sup>. SCD101, a botanical drug with an unclear anti-sickling mechanism which might involve dilution of HbS by affecting the RBC membrane, was well tolerated in a phase Ib study, with a decrease in chronic pain and fatigue and improvement in leg ulcers<sup><a href="#ref-89">89</a></sup>.</p></div><div class=section><a name=d25416e1052 class=n-a></a><h3 class=section-title>Targeting downstream sequelae of sickle hemoglobin polymerization</h3><p class="" id=d25416e1057><i><b>Antioxidant therapy.</b></i> Agents that upregulate antioxidant and/or reactive oxygen species scavenging processes have been evaluated in SCD. Glutamine, a conditionally essential amino acid, is a precursor for nicotinamide adenine dinucleotide (NAD) and improves NAD redox potential. In a randomized, multicenter trial of 230 patients with HbSS or HbSβ<sup>0</sup>-thalassemia, L-glutamine significantly reduced the number of pain crises, hospitalizations, cumulative hospital days, and frequency of acute chest syndrome compared with placebo<sup><a href="#ref-90">90</a></sup>. However, the effect size of L-glutamine in reducing pain crises was relatively small, with only a 25% reduction in the median number of pain crises. L-glutamine was well tolerated, although low-grade nausea, non-cardiac chest pain, fatigue, and musculoskeletal pain occurred more frequently than with placebo. Despite some concerns related to the high dropout rate in the trial (36% L-glutamine arm; 24% placebo arm), L-glutamine was approved by the FDA to reduce the acute complications of SCD in patients 5 years and older<sup><a href="#ref-24">24</a></sup>.</p><p class="" id=d25416e1074>In an open-label pilot trial of oral N-acetylcysteine (NAC), treatment with either 1,200 mg or 2,400 mg daily for 6 weeks increased whole blood glutathione levels and decreased erythrocyte outer membrane phosphatidylserine exposure, plasma levels of advanced glycation products, and cell-free hemoglobin in both groups<sup><a href="#ref-91">91</a></sup>. A randomized, placebo-controlled, double-blind trial of NAC at 600 mg twice daily for 6 months did not decrease the rate of SCD-related pain days per patient year, vaso-occlusive crises, hospital admission days, number of admissions, or days with home analgesic use compared with placebo<sup><a href="#ref-92">92</a></sup>. The safety and efficacy of NAC, administered at a higher dose during pain crisis, is being explored in a phase I/II study (NCT01800526) (<a href="#T2">Table 2</a>).</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Ongoing clinical trials of anti-adhesion agents and antioxidants in sickle cell disease.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d25416e1099 class=n-a></a><thead><a name=d25416e1101 class=n-a></a><tr><a name=d25416e1103 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e1105 class=n-a></a>Mechanism</th><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e1108 class=n-a></a>Drug</th><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e1111 class=n-a></a>Sponsor</th><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e1114 class=n-a></a>NCT number<br class=br>(study<br class=br>acronym)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e1121 class=n-a></a>Clinical phase/status</th><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e1125 class=n-a></a>Intervention</th><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e1128 class=n-a></a>Number/age</th><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e1131 class=n-a></a>Objective</th></tr></thead><tbody><a name=d25416e1136 class=n-a></a><tr><a name=d25416e1138 class=n-a></a><td align=left colspan=1 rowspan=5 valign=top><a name=d25416e1140 class=n-a></a>P-selectin<br class=br>antagonist</td><td align=left colspan=1 rowspan=5 valign=top><a name=d25416e1145 class=n-a></a>Crizanlizumab</td><td align=left colspan=1 rowspan=5 valign=top><a name=d25416e1148 class=n-a></a>Novartis<br class=br>Pharmaceuticals</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1153 class=n-a></a>NCT03264989<br class=br>(SOLACE-<br class=br>adults)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1160 class=n-a></a>Phase II<br class=br>Active,<br class=br>not recruiting </td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1168 class=n-a></a>IV infusion, open-label </td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1171 class=n-a></a>57/16–70 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1174 class=n-a></a>Pharmacokinetics,<br class=br>pharmacodynamics, safety, and<br class=br>efficacy</td></tr><tr><a name=d25416e1182 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1184 class=n-a></a>NCT03814746<br class=br>(STAND)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1189 class=n-a></a>Phase III<br class=br>Recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1194 class=n-a></a>IV infusion every 2 weeks for<br class=br>1<sup>st</sup> month and then monthly<br class=br>for 1 year</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1204 class=n-a></a>240/≥12 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1207 class=n-a></a>Compare efficacy and safety of 5<br class=br>mg/kg and 7.5 mg/kg doses<br class=br>with placebo</td></tr><tr><a name=d25416e1215 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1217 class=n-a></a>NCT04053764<br class=br>(STEADFAST)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1222 class=n-a></a>Phase II<br class=br>Recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1227 class=n-a></a>IV infusion every 2 weeks for<br class=br>1<sup>st</sup> month and then every 4<br class=br>weeks for 51 weeks + SoC vs.<br class=br>SoC alone</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1239 class=n-a></a>170/≥16 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1242 class=n-a></a>Evaluating effect on kidney<br class=br>function (albumin-creatinine ratio,<br class=br>protein-creatinine ratio, estimated<br class=br>glomerular filtration rate)</td></tr><tr><a name=d25416e1252 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1254 class=n-a></a>NCT03938454<br class=br>(SPARTAN)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1259 class=n-a></a>Phase II<br class=br>Recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1264 class=n-a></a>IV infusion every 2 weeks for<br class=br>1<sup>st</sup> month and then every 4<br class=br>weeks x 51 weeks</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1274 class=n-a></a>56/≥16 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1277 class=n-a></a>Evaluate efficacy in priapism,<br class=br>uncomplicated VOC events</td></tr><tr><a name=d25416e1283 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1285 class=n-a></a>NCT03474965</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1288 class=n-a></a>Phase II<br class=br>Recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1293 class=n-a></a>IV infusion every 2 weeks for<br class=br>1<sup>st</sup> month and then every 4<br class=br>weeks</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1303 class=n-a></a>100/6 months–&lt;18<br class=br>years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1308 class=n-a></a>Evaluate pharmacokinetics,<br class=br>pharmacodynamics, safety, and<br class=br>effect on VOC events</td></tr><tr><a name=d25416e1317 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1319 class=n-a></a>Blockade of fcγrIII<br class=br>receptors</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1324 class=n-a></a>IVIG </td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1327 class=n-a></a>Albert Einstein<br class=br>College of<br class=br>Medicine</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1334 class=n-a></a>NCT01757418</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1337 class=n-a></a>Phase I–II<br class=br>Recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1343 class=n-a></a>Single dose of IVIG vs.<br class=br>placebo given within 24 hours<br class=br>of hospitalization</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1350 class=n-a></a>94/12–65 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1353 class=n-a></a>Length of VOC, total opioid<br class=br>use, time to end of VOC, <i>in vitro</i><br class=br>adhesion studies</td></tr><tr><a name=d25416e1363 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1365 class=n-a></a>Antioxidant<br class=br>(increased<br class=br>glutathione)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1372 class=n-a></a>NAC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1375 class=n-a></a>Bloodworks</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1378 class=n-a></a>NCT01800526</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1381 class=n-a></a>Phase I/II<br class=br>Enrolling by<br class=br>invitation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1389 class=n-a></a>IV or oral, NAC<br class=br><br class=br>Part 1: two doses of IV<br class=br>infusion over 8 hours 4 weeks<br class=br>apart or oral<br class=br>NAC for 4 weeks<br class=br><br class=br>Part 2 (during VOC): IV<br class=br>infusion every 6 hours for 5<br class=br>days</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1409 class=n-a></a>20/≥18 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1412 class=n-a></a>Evaluate effect on vWF activity,<br class=br>measures of hemolysis and<br class=br>oxidation In Part 2, evaluate<br class=br>efficacy during VOC</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d25416e1426 class=n-a></a><p id=d25416e1428> IV, intravenous; IVIG, intravenous gammaglobulin; NAC, N-acetylcysteine; SoC, standard of care; VOC, vaso-occlusive crisis; vWF activity, von Willebrand factor activity.</p></div></div></div><p class="" id=d25416e1434><i><b>Anti-adhesive therapy.</b></i> Agents targeting adhesion of blood cells to the endothelium have been investigated in SCD. Crizanlizumab, a humanized monoclonal anti-P-selectin antibody, was recently approved for use in patients 16 years and older for the prevention of vaso-occlusive crises<sup><a href="#ref-25">25</a></sup> based on results of a randomized, double-blind, phase II study which evaluated the benefit of 2.5 mg/kg or 5 mg/kg doses versus placebo. Significantly lower median crisis rate, longer median times to first and second crises, and lower median rate of uncomplicated crises per year were observed with high-dose crizanlizumab compared with placebo following a 52-week treatment period<sup><a href="#ref-93">93</a></sup>. Multiple other studies of crizanlizumab are ongoing (<a href="#T2">Table 2</a>).</p><p class="" id=d25416e1452>Purified poloxamer 188, a nonionic block copolymer surfactant with hemorheologic and antithrombotic properties, was previously shown to significantly decrease the duration of pain episodes, especially in children and patients on hydroxyurea<sup><a href="#ref-94">94</a></sup>. However, a more recent phase III study in children and adults reported no significant effect of purified poloxamer 188 (vepoloxamer or MST-188) on duration of vaso-occlusive crises compared with placebo<sup><a href="#ref-95">95</a></sup>. Rivipansel sodium (formerly GMI-1070) is a small-molecule pan-selectin inhibitor that binds to E-, P-, and L-selectin<sup><a href="#ref-96">96</a></sup>. In a randomized, double-blind, adaptive, phase II trial, treatment with rivipansel during pain crisis produced a significant reduction in the mean cumulative intravenous opioid analgesic use compared to placebo<sup><a href="#ref-97">97</a></sup>. However, despite the promising phase II trial results, the recently completed multicenter phase III RESET trial failed to meet its primary (time to readiness for discharge) and key secondary (time to discharge, cumulative intravenous opioid utilization, and time to discontinuation of intravenous opioids) efficacy endpoints<sup><a href="#ref-98">98</a></sup>.</p><p class="" id=d25416e1475>Heparins inhibit adhesive interactions via P-selectin<sup><a href="#ref-99">99</a>,<a href="#ref-100">100</a></sup>. Tinzaparin, a low-molecular-weight (LMW) heparin, at therapeutic dose reportedly decreased the number of hospital days, the number of days with pain crisis, and the number of days with the most severe pain scores compared with placebo<sup><a href="#ref-101">101</a></sup>. Sevuparin, a derivative of LMW heparin, which retains the P-selectin-binding domain of heparin but largely lacks anticoagulant properties, binds to P- and L-selectins, thrombospondin, fibronectin, and von Willebrand factor, inhibits the adhesion of sickle RBCs to stimulated cultured endothelial cells <i>in vitro</i>, and prevents vaso-occlusion with normalization of blood flow in a mouse model of vaso-occlusion<sup><a href="#ref-102">102</a></sup>. A recently completed randomized, double-blind, placebo-controlled trial found that, although safe, sevuparin did not significantly reduce the time to resolution of vaso-occlusive crisis<sup><a href="#ref-103">103</a></sup>. A phase II feasibility study of therapeutic-dose unfractionated heparin (NCT02098993) was recently terminated for poor enrollment, but a phase III, randomized, placebo-controlled study of tinzaparin in acute chest syndrome is ongoing (NCT02580773).</p><p class="" id=d25416e1500>Intravenous immunoglobulin (IVIG) binds to FcγRIII receptors, inhibits neutrophil adhesion to the endothelium, reduces RBC capture by leukocytes, and reduces Mac-1 activity due to recruitment of Src homology 2-containing tyrosine phosphatase-1<sup><a href="#ref-104">104</a></sup>. IVIG was tolerated at doses of up to 800 mg/kg during acute vaso-occlusive crises and decreased Mac-1 function from baseline<sup><a href="#ref-105">105</a></sup>. A phase II clinical trial of IVIG during acute pain episodes is ongoing (NCT01757418).</p><p class="" id=d25416e1511><i><b>Anti-inflammatory agents.</b></i> Multiple approaches to downregulate inflammatory pathways have been evaluated. Initial clinical responses with the use of steroids for pain crisis and acute chest syndrome were followed by “rebound” pain episodes and re-admissions after treatment discontinuation<sup><a href="#ref-106">106</a>,<a href="#ref-107">107</a></sup>. Inhaled corticosteroids did not significantly reduce the morbidity of acute chest syndrome in a retrospective cohort study<sup><a href="#ref-108">108</a></sup>, but inhaled mometasone significantly reduced daily pain diary scores and levels of soluble vascular adhesion molecule-1 over the 16-week treatment period in another single-center, placebo-controlled trial<sup><a href="#ref-109">109</a></sup>.</p><p class="" id=d25416e1532>The activation of iNKT cells is downregulated by the activation of adenosine A2A receptors (A<sub>2A</sub>R)<sup><a href="#ref-110">110</a></sup>. Regadenoson, a partially selective A<sub>2A</sub>R agonist, was reportedly safe but did not decrease length of hospital stay, total opioid use, or pain scores compared to placebo during pain crises<sup><a href="#ref-111">111</a>,<a href="#ref-112">112</a></sup>. In addition, there were no significant differences between regadenoson and placebo regarding the number of patients exhibiting a greater than 30% reduction in activated iNKT cells. The anti-iNKT cell monoclonal antibody NKTT120 resulted in rapid, specific, and continuous iNKT cell depletion in a single-ascending-dose study<sup><a href="#ref-113">113</a></sup>, but further studies are required to determine its long-term safety and efficacy.</p><p class="" id=d25416e1556>Statins have benefits independent of their cholesterol-lowering effect. In a pilot study, simvastatin was well tolerated, increased levels of NO metabolites, and decreased C-reactive protein (CRP) and interleukin-6 levels<sup><a href="#ref-114">114</a></sup>. Daily treatment with simvastatin for 3 months significantly reduced pain crises, oral analgesic use, and levels of high-sensitivity CRP, soluble E-selectin, soluble ICAM-1, soluble ICAM-3, and VEGF<sup><a href="#ref-115">115</a></sup>, providing supporting data for conduct of a placebo-controlled trial. Atorvastatin was well tolerated in a pilot study but did not improve endothelial function or decrease albuminuria<sup><a href="#ref-116">116</a></sup>.</p><p class="" id=d25416e1572>Long-chain omega-3 polyunsaturated fatty acids such as eicosapentaenoic acid (EPA [n-3]) and docosahexaenoic acid (DHA [n-6]) provide benefit to individuals with chronic inflammatory disorders. In a randomized, single-center study, daily omega-3 administered in capsule form significantly lowered the occurrence of vaso-occlusive events, severe anemia, blood transfusion requirements, and school absence compared with placebo<sup><a href="#ref-117">117</a></sup>. More recently, a randomized, placebo-controlled study of different doses of SC411, a novel DHA ethyl ester formulation with high DHA bioavailability, found it was well tolerated, with significant reductions in d-dimer and E-selectin and an increase in hemoglobin<sup><a href="#ref-118">118</a></sup>. SC411 also significantly reduced electronic diary-recorded pain episodes, analgesic use at home, and days absent from school but did not significantly lower pain crises in the pooled active groups compared to placebo.</p><p class="" id=d25416e1583>Preliminary results suggest that the monoclonal anti-IL1β antibody canakinumab (ACZ885) is well tolerated and not associated with major side effects in SCD<sup><a href="#ref-119">119</a></sup>.</p><p class="" id=d25416e1590><i><b>Anticoagulant and antiplatelet therapies.</b></i> With abundant evidence that SCD is a hypercoagulable state<sup><a href="#ref-21">21</a></sup>, combined with data that coagulation and platelet activation may play roles in disease pathophysiology<sup><a href="#ref-120">120</a>–<a href="#ref-124">124</a></sup>, multiple studies have evaluated the effects of anticoagulants and antiplatelet agents in SCD. Although treatment with the LMW heparin tinzaparin produced more rapid resolution of pain crisis and shorter duration of hospitalization than placebo<sup><a href="#ref-101">101</a></sup>, it is uncertain whether the reported beneficial effects were a result of its anticoagulant or anti-adhesive effects. The results of a pilot study of the direct oral anticoagulant rivaroxaban in SCD are awaited (NCT02072668).</p><p class="" id=d25416e1611>Multiple relatively small studies of aspirin have reported modest benefit at best<sup><a href="#ref-125">125</a>–<a href="#ref-127">127</a></sup>, although one study reported an increase in oxygen affinity, hemoglobin level, and RBC lifespan<sup><a href="#ref-126">126</a></sup>. A pilot study of the glycoprotein IIb/IIIa inhibitor eptifibatide showed that it was safe during acute pain episodes but did not reduce the time to resolution of such episodes<sup><a href="#ref-128">128</a></sup>. Ticlopidine, a P2Y<sub>12</sub> ADP-receptor antagonist, reportedly decreased the number of pain episodes, mean duration of pain episodes, and severity of such episodes<sup><a href="#ref-129">129</a></sup>. However, a more recent phase III trial of prasugrel, a newer generation P2Y<sub>12</sub> receptor blocker, showed no significant reduction of the frequency of pain episodes in children with SCD<sup><a href="#ref-130">130</a></sup>. Ticagrelor, a reversible P2Y<sub>12</sub> receptor blocker, was well tolerated in children<sup><a href="#ref-131">131</a></sup> and young adults<sup><a href="#ref-132">132</a></sup> but had no beneficial effects on pain. A phase III study to determine the efficacy of ticagrelor in reducing vaso-occlusive crises in children is ongoing<sup><a href="#ref-133">133</a></sup> (<a href="#T3">Table 3</a>).</p><a name=T3 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 3. Ongoing clinical trials of anticoagulants, antiplatelet agents, anti-inflammatory agents, and nitric oxide-related drugs in sickle cell disease</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" frame=box rules=all><a name=d25416e1674 class=n-a></a><thead><a name=d25416e1676 class=n-a></a><tr><a name=d25416e1678 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e1680 class=n-a></a>Mechanism</th><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e1683 class=n-a></a>Drug</th><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e1686 class=n-a></a>Sponsor</th><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e1689 class=n-a></a>NCT number<br class=br>(study acronym)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e1694 class=n-a></a>Clinical phase/<br class=br>status</th><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e1700 class=n-a></a>Intervention</th><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e1703 class=n-a></a>Number/age</th><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e1706 class=n-a></a>Objective</th></tr></thead><tbody><a name=d25416e1711 class=n-a></a><tr><a name=d25416e1713 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1715 class=n-a></a>Anticoagulant,<br class=br>anti-adhesive (P-<br class=br>selectin blocker) </td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1722 class=n-a></a>Tinzaparin<br class=br>(low-molecular-weight<br class=br>heparin)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1729 class=n-a></a>Assistance Publique<br class=br>–Hopitaux de Paris,<br class=br>LEO pharma</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1736 class=n-a></a>NCT02580773<br class=br>(TASC)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1741 class=n-a></a>Phase III<br class=br>Unknown status</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1747 class=n-a></a>Subcutaneous therapeutic vs.<br class=br>prophylactic dose for 7 days </td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1752 class=n-a></a>200/≥18 years<br class=br></td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1756 class=n-a></a>Time to ACS resolution, bleeding<br class=br>events, hospital mortality</td></tr><tr><a name=d25416e1762 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1764 class=n-a></a>Antiplatelet</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1767 class=n-a></a>Ticagrelor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1770 class=n-a></a>AstraZeneca</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1773 class=n-a></a>NCT03615924<br class=br>(HESTIA3)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1778 class=n-a></a>Phase III<br class=br>Active, not recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1784 class=n-a></a>Oral ticagrelor vs. placebo for<br class=br>at least 12 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1789 class=n-a></a>193/2–17 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1792 class=n-a></a>Evaluate efficacy in decreasing VOC,<br class=br>acute chest syndrome, duration of<br class=br>VOC, QOL measures</td></tr><tr><a name=d25416e1800 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1802 class=n-a></a>Antithrombotic,<br class=br>anti-inflammatory</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1807 class=n-a></a>Defibrotide</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1810 class=n-a></a>New York Medical<br class=br>College</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1815 class=n-a></a>NCT03805581</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1818 class=n-a></a>Phase II Recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1822 class=n-a></a>Intravenous, every 6 hours<br class=br>during ACS event for<br class=br>maximum of 7 days</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1829 class=n-a></a>20/2–40 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1832 class=n-a></a>Safety (allergic reaction, bleeding),<br class=br>improvement in clinical signs of ACS</td></tr><tr><a name=d25416e1838 class=n-a></a><td align=left colspan=1 rowspan=6 valign=top><a name=d25416e1840 class=n-a></a>Anti-inflammatory</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1843 class=n-a></a>Mometasone</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1846 class=n-a></a>Jeffery Glassberg</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1849 class=n-a></a>NCT03758950<br class=br>(IMPROVE2)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1854 class=n-a></a>Phase II<br class=br>Recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1860 class=n-a></a>Inhaled, one puff daily vs.<br class=br>placebo for 48 weeks</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1865 class=n-a></a>80/≥18 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1868 class=n-a></a>Change in soluble VCAM-1,<br class=br>hemoglobin, markers of hemolysis,<br class=br>leukocyte count, QOL measures</td></tr><tr><a name=d25416e1876 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1878 class=n-a></a>Canakinumab<br class=br>(anti-IL1β antibody)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1883 class=n-a></a>Novartis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1886 class=n-a></a>NCT02961218</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1889 class=n-a></a>Phase II<br class=br>Active, not recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1894 class=n-a></a>Subcutaneous, monthly for 6<br class=br>months vs. placebo, followed<br class=br>by 6-month open-label<br class=br>extension</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1904 class=n-a></a>49/8–20 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1907 class=n-a></a>Reduction of average daily pain, days<br class=br>missed from school, blood counts,<br class=br>pharmacokinetics, hs-CRP, measures<br class=br>of hemolysis</td></tr><tr><a name=d25416e1918 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1920 class=n-a></a>Docosahexaenoic acid<br class=br>and eicosapentaenoic<br class=br>acid</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1927 class=n-a></a>Thomas Jefferson<br class=br>University</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1932 class=n-a></a>NCT01202812</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1935 class=n-a></a>Phase II<br class=br>Not yet recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1940 class=n-a></a>Oral, daily for 6 months vs.<br class=br>placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1946 class=n-a></a>48/10–19 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1949 class=n-a></a>Decrease inflammatory biomarkers,<br class=br>QOL</td></tr><tr><a name=d25416e1955 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1957 class=n-a></a>Docosahexaenoic acid<br class=br>(SC411)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1962 class=n-a></a>Micelle BioPharma</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1965 class=n-a></a>NCT02973360<br class=br>(SCOT study)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1970 class=n-a></a>Phase II<br class=br>Active, not recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1975 class=n-a></a>Oral for 8 weeks vs. placebo<br class=br>followed by 49-month open-<br class=br>label extension</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1983 class=n-a></a>68/5–17 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1986 class=n-a></a>Safety, pharmacokinetics, effect on<br class=br>VOC</td></tr><tr><a name=d25416e1992 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1994 class=n-a></a>Omega-3-fatty acid</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e1997 class=n-a></a>Sultan Qaboos<br class=br>University</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2002 class=n-a></a>NCT02525107</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2005 class=n-a></a>Phase III<br class=br>Recruitment status<br class=br>unknown</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2012 class=n-a></a>Oral, daily for 52 weeks vs.<br class=br>placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2018 class=n-a></a>280/13–70 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2021 class=n-a></a>Effect on VOC, duration of<br class=br>hospitalization, RBC membrane fatty<br class=br>acid profile</td></tr><tr><a name=d25416e2029 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2031 class=n-a></a>Rifaximin (antibiotic,<br class=br>decrease aged<br class=br>neutrophils)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2038 class=n-a></a>New York Medical<br class=br>College</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2043 class=n-a></a>NCT03719729</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2046 class=n-a></a>Phase II<br class=br>Recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2051 class=n-a></a>Oral, twice daily for 1 year</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2055 class=n-a></a>20/18–70 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2058 class=n-a></a>Safety, frequency of hospitalizations for<br class=br>VOCs, duration of hospitalizations, RBC<br class=br>transfusions, QOL measures</td></tr><tr><a name=d25416e2066 class=n-a></a><td align=left colspan=1 rowspan=2 valign=top><a name=d25416e2068 class=n-a></a><br class=br><br class=br>Increased NO<br class=br>production</td><td align=left colspan=1 rowspan=2 valign=top><a name=d25416e2075 class=n-a></a><br class=br><br class=br>Arginine</td><td align=left colspan=1 rowspan=2 valign=top><a name=d25416e2080 class=n-a></a><br class=br><br class=br>Emory University </td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2085 class=n-a></a>NCT02447874</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2088 class=n-a></a>Phase I/II<br class=br>Enrolling by invitation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2094 class=n-a></a>Intravenous, three times a day<br class=br>for maximum of 7 days</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2099 class=n-a></a>21/7–21 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2102 class=n-a></a>Pharmacokinetics, NO metabolites</td></tr><tr><a name=d25416e2106 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2108 class=n-a></a>NCT02536170</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2111 class=n-a></a>Phase II<br class=br>Recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2116 class=n-a></a>Intravenous, three times<br class=br>a day through duration of<br class=br>hospitalization</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2123 class=n-a></a>114/3–21 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2126 class=n-a></a>Effect on VOC, including total<br class=br>parenteral opioid use, length of hospital<br class=br>stay, resolution of VOC</td></tr><tr><a name=d25416e2135 class=n-a></a><td align=left colspan=1 rowspan=5 valign=top><a name=d25416e2137 class=n-a></a>Vasodilator</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2140 class=n-a></a>Olinciguat (IW-1701)<br class=br>(soluble guanylate<br class=br>cyclase stimulator)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2147 class=n-a></a>Cyclerion<br class=br>therapeutics</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2152 class=n-a></a>NCT03285178</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2155 class=n-a></a>Phase II<br class=br>Recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2161 class=n-a></a>Oral, daily 12 weeks vs.<br class=br>placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2166 class=n-a></a>88/16–70 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2169 class=n-a></a>Safety and tolerability,<br class=br>pharmacokinetics, pharmacodynamics</td></tr><tr><a name=d25416e2175 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2177 class=n-a></a>Riociguat (soluble<br class=br>guanylate cyclase<br class=br>stimulator)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2184 class=n-a></a>Mark Gladwin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2187 class=n-a></a>NCT02633397</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2190 class=n-a></a>Phase II<br class=br>Recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2195 class=n-a></a>Oral, three times daily for 12<br class=br>weeks</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2201 class=n-a></a>100/≥18 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2204 class=n-a></a>Safety, changes in pain intensity,<br class=br>SCD-related complications, functional<br class=br>capacity, blood pressure, plasma<br class=br>NT-proBNP, changes in laboratory<br class=br>measures, TRV</td></tr><tr><a name=d25416e2216 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2218 class=n-a></a>IMR-687 (selective<br class=br>phosphodiesterase-9<br class=br>inhibitor)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2225 class=n-a></a>Imara</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2228 class=n-a></a>NCT03401112</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2231 class=n-a></a>Phase IIa<br class=br>Recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2236 class=n-a></a>Oral, daily for 24 weeks vs.<br class=br>placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2242 class=n-a></a>70/18–55 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2245 class=n-a></a>Safety, pharmacokinetics</td></tr><tr><a name=d25416e2249 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2251 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2253 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2255 class=n-a></a>NCT04053803<br class=br></td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2259 class=n-a></a>Phase II<br class=br>Enrolling by invitation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2264 class=n-a></a>Oral, daily for 49 months,<br class=br>open-label extension</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2270 class=n-a></a>70/≥18 years<br class=br></td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2274 class=n-a></a>Safety, change in hemoglobin, HbF,<br class=br>soluble adhesion markers, renal and<br class=br>cardiac function, QOL</td></tr><tr><a name=d25416e2282 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2284 class=n-a></a>Ambrisentan<br class=br>(endothelin receptor A<br class=br>antagonist)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2291 class=n-a></a>Augusta University</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2294 class=n-a></a>NCT02712346</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2297 class=n-a></a>Phase I<br class=br>Active, not recruiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2302 class=n-a></a>Oral, once daily for 12 weeks</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2306 class=n-a></a>26/18–65 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2309 class=n-a></a>Safety and tolerability,<br class=br>microalbuminuria/proteinuria,<br class=br>TRV, inflammatory markers, pain<br class=br>questionnaire </td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d25416e2323 class=n-a></a><p id=d25416e2325> ACS, acute chest syndrome; HbF, fetal hemoglobin; hs-CRP, high-sensitivity C-reactive protein; NO, nitric oxide; NT-proBNP, N-terminal probrain natriuretic peptide; QOL, quality of life; TRV, echocardiography-derived tricuspid regurgitant jet velocity; VCAM-1, vascular cell adhesion molecule-1; VOC, vaso-occlusive crisis; vWF, von Willebrand factor.</p></div></div></div><p class="" id=d25416e2331><i><b>Nitric oxide and related agents.</b></i> With the role of hemolysis in NO scavenging and subsequent endothelial dysfunction, NO and related agents may be beneficial in SCD<sup><a href="#ref-134">134</a></sup>. Inhaled NO did not improve time to resolution of pain crisis, length of hospitalization, opioid usage, or rate of acute chest syndrome compared with placebo<sup><a href="#ref-135">135</a></sup>. In another study, inhaled NO did not reduce the rate of treatment failure in adult patients with mild to moderate acute chest syndrome<sup><a href="#ref-136">136</a></sup>. However, L-arginine, an NO precursor, significantly decreased total parenteral opioid use and pain scores at discharge compared to placebo in children, although there was no difference in length of hospital stay<sup><a href="#ref-137">137</a></sup>. Furthermore, supplementation of adult patients on hydroxyurea with oral arginine significantly increased the level of NO metabolites and reduced the frequency of pain crises versus placebo following 4 months of treatment<sup><a href="#ref-138">138</a></sup>. Sildenafil, a phosphodiesterase-5 inhibitor which increases NO-mediated effects by inhibiting the degradation of cyclic guanosine monophosphate (cGMP), was associated with more frequent serious adverse events, predominantly hospitalization for pain, compared with placebo<sup><a href="#ref-139">139</a></sup>. No evidence of a treatment effect of sildenafil was seen on evaluated study outcomes. Studies of soluble guanylate cycle stimulators, riociguat (NCT02633397) and olinciguat/IW-1701 (NCT03285178), and the phosphodiesterase-9 inhibitor IMR-687 (NCT03401112; NCT04053803) are ongoing (<a href="#T3">Table 3</a>).</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d25416e2369>Summary</h2><p class="" id=d25416e2372>Recent advances in drug development for SCD raise important issues related to the use and availability of these agents. With limited availability of allogeneic bone marrow transplantation and gene therapy, especially in low- and middle-income countries, the number of recently approved drugs offers hope for further improved outcomes in SCD. Choice of initial drug therapy may be guided by a patient’s clinical sub-phenotype as well as the cost of the drug (<a href="#T4">Table 4</a>). Patients with frequent vaso-occlusive complications (acute pain episodes, acute chest syndrome) may benefit from hydroxyurea, L-glutamine, and crizanlizumab, while those with increased hemolytic anemia (or quite possibly complications related to hemolytic anemia) may benefit from hydroxyurea and voxelotor. However, more studies are required before definite recommendations can be made regarding the effect of voxelotor on SCD-related complications. As with other chronic disease conditions, it is important to consider the cost of the drug when deciding on initial therapy. Hydroxyurea is much cheaper than L-glutamine, crizanlizumab, and voxelotor and is likely more cost effective as initial therapy for vaso-occlusive complications and hemolytic anemia. However, with the complex pathophysiology of SCD and the limited clinical efficacy of available pharmacological therapies, it is unlikely that a single drug will ameliorate all SCD-related complications. As such, the availability of multiple drugs offers an opportunity for combination therapy based on different mechanisms of action and non-overlapping side effect profiles. Although more studies are required to evaluate the effect of combinations of these drugs, all of the recently approved agents were tested in combination with hydroxyurea. These studies showed benefit whether or not participants received concomitant hydroxyurea, with no increased toxicity. Despite potential benefits, combination therapy involving the use of multiple drugs increases the likelihood of decreased medication adherence owing to polypharmacy. Like in other chronic diseases, however, this problem may be somewhat ameliorated by the development of pills that contain more than one active drug.</p><a name=T4 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 4. Summary characteristics of FDA-approved drugs for sickle cell disease.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d25416e2389 class=n-a></a><thead><a name=d25416e2391 class=n-a></a><tr><a name=d25416e2393 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d25416e2395 class=n-a></a></th><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e2397 class=n-a></a>Hydroxyurea</th><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e2400 class=n-a></a>L-Glutamine</th><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e2403 class=n-a></a>Crizanlizumab</th><th align=left colspan=1 rowspan=1 valign=top><a name=d25416e2406 class=n-a></a>Voxelotor</th></tr></thead><tbody><a name=d25416e2411 class=n-a></a><tr><a name=d25416e2413 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2415 class=n-a></a>Age (years)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2418 class=n-a></a>≥2 </td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2421 class=n-a></a>≥5</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2424 class=n-a></a>≥16 </td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2427 class=n-a></a>≥12</td></tr><tr><a name=d25416e2430 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2432 class=n-a></a>Genotypes </td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2435 class=n-a></a>HbSS, HbSβ<sup>0</sup> thalassemia</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2441 class=n-a></a>All genotypes (only<br class=br>studied in HbSS, HbSβ<sup>0</sup><br class=br>thalassemia)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2450 class=n-a></a>All genotypes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2453 class=n-a></a>All genotypes</td></tr><tr><a name=d25416e2457 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2459 class=n-a></a>Mechanism of action</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2462 class=n-a></a>Multiple, but primarily by<br class=br>increasing HbF production</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2467 class=n-a></a>Uncertain, but thought<br class=br>to reduce NAD redox<br class=br>potential, possible<br class=br>decrease in cell<br class=br>adhesion</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2478 class=n-a></a>Anti P-selectin inhibitor<br class=br>(decreases adhesion<br class=br>of WBCs and RBCs to<br class=br>endothelium)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2487 class=n-a></a>Decreases HbS<br class=br>polymerization by<br class=br>increasing Hb–oxygen<br class=br>affinity</td></tr><tr><a name=d25416e2497 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2499 class=n-a></a>Route of administration</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2502 class=n-a></a>Oral (capsules/tablets)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2505 class=n-a></a>Oral (powder)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2508 class=n-a></a>Intravenous</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2511 class=n-a></a>Oral (tablets)</td></tr><tr><a name=d25416e2515 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2517 class=n-a></a>Clinical effects<br class=br>of therapy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2522 class=n-a></a>Decreased frequency of VOC,<br class=br>decreased frequency of ACS,<br class=br>decreased hospitalization,<br class=br>decreased RBC transfusion<br class=br>requirement, decreased stroke risk</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2533 class=n-a></a>Decreased frequency<br class=br>of VOC, decreased<br class=br>frequency of<br class=br>ACS, decreased<br class=br>hospitalization</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2544 class=n-a></a>Decreased frequency<br class=br>of VOC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2549 class=n-a></a>Increased hemoglobin</td></tr><tr><a name=d25416e2554 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2556 class=n-a></a>Effect size for primary<br class=br>endpoint (% change<br class=br>and IRR)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2563 class=n-a></a>44% decrease in VOC per year<br class=br>(median from 4.5 to 2.5), IRR =<br class=br>0.56</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2570 class=n-a></a>25% decrease in VOC in<br class=br>48 weeks (median from<br class=br>4 to 3), IRR = 0.75</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2577 class=n-a></a>45% decrease in crisis<br class=br>rate per year (median<br class=br>from 3 to 1.6), IRR =<br class=br>0.55</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2586 class=n-a></a>5.5-fold increase in the<br class=br>hemoglobin responders<br class=br>(9% to 59%) at 24<br class=br>weeks, incidence<br class=br>proportion ratio = 6.6<a href="#TFN5">*</a></td></tr><tr><a name=d25416e2600 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2602 class=n-a></a>Common toxicities</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2605 class=n-a></a>Myelosuppression, skin<br class=br>hyperpigmentation, nail<br class=br>discoloration, teratogenicity,<br class=br>decreased sperm counts, nausea<br class=br>and vomiting</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2616 class=n-a></a>Constipation, nausea,<br class=br>headaches, abdominal<br class=br>pain</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2623 class=n-a></a>Nausea, arthralgia</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2626 class=n-a></a>Headache, diarrhea,<br class=br>nausea</td></tr><tr><a name=d25416e2632 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2634 class=n-a></a>Pharmacokinetics</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2637 class=n-a></a>Excreted via kidneys Adjust dose<br class=br>for eGFR &lt;60 mL/min/1.73 m<sup>2</sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2644 class=n-a></a>Use with caution with<br class=br>hepatic and renal<br class=br>impairment, but no<br class=br>recommended dose<br class=br>adjustment</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2655 class=n-a></a>No dosage<br class=br>adjustments in<br class=br>manufacturer labeling<br class=br>for renal and hepatic<br class=br>impairment (not tested<br class=br>in ESRD)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2668 class=n-a></a>No dosage adjustment<br class=br>for renal impairment,<br class=br>but not yet studied in<br class=br>ESRD requiring dialysis<br class=br>Dose reduction for<br class=br>severe liver disease<br class=br>(Child Pugh class C)</td></tr><tr><a name=d25416e2685 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2687 class=n-a></a>Cost</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2690 class=n-a></a>$</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2693 class=n-a></a>$$$</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2696 class=n-a></a>$$$$$</td><td align=left colspan=1 rowspan=1 valign=top><a name=d25416e2699 class=n-a></a>$$$$$</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=TFN4 class=n-a></a><p id=d25416e2709><span class=warning></span> ACS, acute chest syndrome; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; FDA, US Food and Drug Administration; Hb, hemoglobin; HbF, fetal hemoglobin; HbS, sickle hemoglobin; IRR, incidence rate ratio; NAD, nicotinamide adenine dinucleotide; RBC, red blood cell; VOC, vaso-occlusive crisis; WBC, white blood cell.</p></div><div class=footnote><a name=TFN5 class=n-a></a><p id=d25416e2718>* Patients treated with 1,500 mg of voxelotor had 6.6 times increased proportion of hemoglobin responders (&gt;1 g/dL increase from baseline at 24 weeks)</p></div></div></div><p class="" id=d25416e2724>It is particularly important that ongoing trials of novel drugs for SCD involve individuals in resource-limited countries where the burden of disease is high. This offers patients access to potentially disease-modifying therapies but, perhaps equally as important, contributes substantially to capacity building by improving local infrastructure, strengthening health systems, involving local leaders as collaborators, and training local providers. Furthermore, trials of novel agents in sub-Saharan Africa provide data on the effects of these therapies in a setting with fewer resources and unique challenges, including a high prevalence of malnutrition and infections such as malaria. With the high cost of recently approved agents, mechanisms to ensure affordable access to these drugs should be established. A situation where novel agents are tested in resource-limited countries but patients in these countries are unable to afford such drugs following approval is unacceptable. Finally, studies evaluating the effects of recently approved drugs on organ damage are needed. Demonstration that these agents prevent or decrease end-organ damage would provide additional evidence for the role of drug therapies in improving outcomes in SCD.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d25416e2731 class=n-a></a><h2 class=main-title id=d25416e2733>Acknowledgements</h2><p class="" id=d25416e2736>The authors thank Dr. Joacy Gerard Matthias and Dr. Matthew P. Smeltzer (Both from the Division of Epidemiology, Biostatistics, and Environmental Health, School of Public Health, University of Memphis, Memphis, Tennessee, USA) for helping to ascertain the drug effect sizes.</p></div><div class=back-section><a name=d25416e2740 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading is-hidden"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d26360>References</h2><div class="section ref-list"><a name=d25416e2740 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d25416e2747 class=n-a></a>Piel FB, Hay SI, Gupta S, <i> et al.</i>: Global burden of sickle cell anaemia in children under five, 2010-2050: Modelling based on demographics, excess mortality, and interventions. <i>PLoS Med.</i> 2013; <b>10</b>(7): e1001484. <a target=xrefwindow id=d25416e2758 href="http://www.ncbi.nlm.nih.gov/pubmed/23874164">PubMed Abstract </a> | <a target=xrefwindow id=d25416e2761 href="https://doi.org/10.1371/journal.pmed.1001484">Publisher Full Text </a> | <a target=xrefwindow id=d25416e2765 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3712914">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d25416e2774 class=n-a></a>Grosse SD, Odame I, Atrash HK, <i> et al.</i>: Sickle cell disease in Africa: A neglected cause of early childhood mortality. <i>Am J Prev Med.</i> 2011; <b>41</b>(6 Suppl 4): S398–405. <a target=xrefwindow id=d25416e2785 href="http://www.ncbi.nlm.nih.gov/pubmed/22099364">PubMed Abstract </a> | <a target=xrefwindow id=d25416e2788 href="https://doi.org/10.1016/j.amepre.2011.09.013">Publisher Full Text </a> | <a target=xrefwindow id=d25416e2792 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3708126">Free Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d25416e2801 class=n-a></a>Telfer P, Coen P, Chakravorty S, <i> et al.</i>: Clinical outcomes in children with sickle cell disease living in England: A neonatal cohort in East London. <i>Haematologica.</i> 2007; <b>92</b>(7): 905–12. <a target=xrefwindow id=d25416e2812 href="http://www.ncbi.nlm.nih.gov/pubmed/17606440">PubMed Abstract </a> | <a target=xrefwindow id=d25416e2815 href="https://doi.org/10.3324/haematol.10937">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d25416e2824 class=n-a></a>Quinn CT, Rogers ZR, McCavit TL, <i> et al.</i>: Improved survival of children and adolescents with sickle cell disease. <i>Blood.</i> 2010; <b>115</b>(17): 3447–52. <a target=xrefwindow id=d25416e2835 href="http://www.ncbi.nlm.nih.gov/pubmed/20194891">PubMed Abstract </a> | <a target=xrefwindow id=d25416e2838 href="https://doi.org/10.1182/blood-2009-07-233700">Publisher Full Text </a> | <a target=xrefwindow id=d25416e2842 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2867259">Free Full Text </a></span><div class=note><a name=d25416e2844 class=n-a></a><p class=first id=d25416e2845><a target=xrefwindow href="https://facultyopinions.com/prime/3899956" id=d25416e2846>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d25416e2855 class=n-a></a>Couque N, Girard D, Ducrocq R, <i> et al.</i>: Improvement of medical care in a cohort of newborns with sickle-cell disease in North Paris: Impact of national guidelines. <i>Br J Haematol.</i> 2016; <b>173</b>(6): 927–37. <a target=xrefwindow id=d25416e2866 href="http://www.ncbi.nlm.nih.gov/pubmed/27062606">PubMed Abstract </a> | <a target=xrefwindow id=d25416e2869 href="https://doi.org/10.1111/bjh.14015">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d25416e2879 class=n-a></a>Elmariah H, Garrett ME, de Castro LM, <i> et al.</i>: Factors associated with survival in a contemporary adult sickle cell disease cohort. <i>Am J Hematol.</i> 2014; <b>89</b>(5): 530–5. <a target=xrefwindow id=d25416e2890 href="http://www.ncbi.nlm.nih.gov/pubmed/24478166">PubMed Abstract </a> | <a target=xrefwindow id=d25416e2893 href="https://doi.org/ 10.1002/ajh.23683">Publisher Full Text </a> | <a target=xrefwindow id=d25416e2897 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3988218">Free Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d25416e2906 class=n-a></a>Gardner K, Douiri A, Drasar E, <i> et al.</i>: Survival in adults with sickle cell disease in a high-income setting. <i>Blood.</i> 2016; <b>128</b>(10): 1436–8. <a target=xrefwindow id=d25416e2917 href="http://www.ncbi.nlm.nih.gov/pubmed/27439910">PubMed Abstract </a> | <a target=xrefwindow id=d25416e2920 href="https://doi.org/10.1182/blood-2016-05-716910">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d25416e2929 class=n-a></a>Maitra P, Caughey M, Robinson L, <i> et al.</i>: Risk factors for mortality in adult patients with sickle cell disease: A meta-analysis of studies in North America and Europe. <i>Haematologica.</i> 2017; <b>102</b>(4): 626–36. <a target=xrefwindow id=d25416e2940 href="http://www.ncbi.nlm.nih.gov/pubmed/28104703">PubMed Abstract </a> | <a target=xrefwindow id=d25416e2943 href="https://doi.org/10.3324/haematol.2016.153791">Publisher Full Text </a> | <a target=xrefwindow id=d25416e2947 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5395103">Free Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d25416e2956 class=n-a></a>DeBaun MR, Ghafuri DL, Rodeghier M, <i> et al.</i>: Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: A pooled analysis. <i>Blood.</i> 2019; <b>133</b>(6): 615–7. <a target=xrefwindow id=d25416e2967 href="http://www.ncbi.nlm.nih.gov/pubmed/30530750">PubMed Abstract </a> | <a target=xrefwindow id=d25416e2970 href="https://doi.org/10.1182/blood-2018-10-880575">Publisher Full Text </a> | <a target=xrefwindow id=d25416e2974 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6367648 ">Free Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d25416e2983 class=n-a></a>Fitzhugh CD, Abraham AA, Tisdale JF, <i> et al.</i>: Hematopoietic stem cell transplantation for patients with sickle cell disease: Progress and future directions. <i>Hematol Oncol Clin of North Am.</i> 2014; <b>28</b>(6): 1171–85. <a target=xrefwindow id=d25416e2994 href="http://www.ncbi.nlm.nih.gov/pubmed/ 25459186">PubMed Abstract </a> | <a target=xrefwindow id=d25416e2997 href="https://doi.org/10.1016/j.hoc.2014.08.014">Publisher Full Text </a> | <a target=xrefwindow id=d25416e3001 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4254544">Free Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d25416e3010 class=n-a></a>Ribeil JA, Hacein-Bey-Abina S, Payen E, <i> et al.</i>: Gene Therapy in a Patient with Sickle Cell Disease. <i>N Engl J Med.</i> 2017; <b>376</b>(9): 848–55. <a target=xrefwindow id=d25416e3021 href="http://www.ncbi.nlm.nih.gov/pubmed/28249145">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3024 href="https://doi.org/10.1056/NEJMoa1609677">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d25416e3034 class=n-a></a>Epstein FH, Bunn HF: Pathogenesis and Treatment of Sickle Cell Disease. <i>N Engl J Med.</i> 1997; <b>337</b>(11): 762–9. <a target=xrefwindow id=d25416e3042 href="http://www.ncbi.nlm.nih.gov/pubmed/9287233">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3045 href="https://doi.org/10.1056/NEJM199709113371107">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d25416e3054 class=n-a></a>Rees DC, Williams TN, Gladwin MT: Sickle-cell disease. <i>Lancet.</i> 2010; <b>376</b>(9757): 2018–31. <a target=xrefwindow id=d25416e3062 href="http://www.ncbi.nlm.nih.gov/pubmed/21131035">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3065 href="https://doi.org/10.1016/S0140-6736(10)61029-X">Publisher Full Text </a></span><div class=note><a name=d25416e3067 class=n-a></a><p class=first id=d25416e3068><a target=xrefwindow href="https://facultyopinions.com/prime/732858103" id=d25416e3069>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d25416e3078 class=n-a></a>Lawson V: Turned on by danger: Activation of CD1d-restricted invariant natural killer T cells. <i>Immunology.</i> 2012; <b>137</b>(1): 20–7. <a target=xrefwindow id=d25416e3086 href="http://www.ncbi.nlm.nih.gov/pubmed/22734667">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3089 href="https://doi.org/10.1111/j.1365-2567.2012.03612.x">Publisher Full Text </a> | <a target=xrefwindow id=d25416e3092 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3449243">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d25416e3101 class=n-a></a>Reiter CD, Wang X, Tanus-Santos JE, <i> et al.</i>: Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. <i>Nat Med.</i> 2002; <b>8</b>(12): 1383–9. <a target=xrefwindow id=d25416e3112 href="http://www.ncbi.nlm.nih.gov/pubmed/12426562">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3115 href="https://doi.org/10.1038/nm1202-799">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d25416e3124 class=n-a></a>Repka T, Hebbel RP: Hydroxyl radical formation by sickle erythrocyte membranes: Role of pathologic iron deposits and cytoplasmic reducing agents. <i>Blood.</i> 1991; <b>78</b>(10): 2753–8. <a target=xrefwindow id=d25416e3132 href="http://www.ncbi.nlm.nih.gov/pubmed/1668610">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3135 href="https://doi.org/10.1182/blood.V78.10.2753.bloodjournal78102753">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d25416e3144 class=n-a></a>de Caterina R, Libby P, Peng HB, <i> et al.</i>: Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. <i>J Clin Invest.</i> 1995; <b>96</b>(1): 60–8. <a target=xrefwindow id=d25416e3155 href="http://www.ncbi.nlm.nih.gov/pubmed/7542286">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3158 href="https://doi.org/10.1172/JCI118074">Publisher Full Text </a> | <a target=xrefwindow id=d25416e3162 href="http://www.ncbi.nlm.nih.gov/pmc/articles/185173">Free Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d25416e3172 class=n-a></a>Palmer RMJ, Ashton DS, Moncada S: Vascular endothelial cells synthesize nitric oxide from L-arginine. <i>Nature.</i> 1988; <b>333</b>(6174): 664–6. <a target=xrefwindow id=d25416e3180 href="http://www.ncbi.nlm.nih.gov/pubmed/3131684">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3183 href="https://doi.org/10.1038/333664a0">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d25416e3192 class=n-a></a>Kato GJ, Gladwin MT, Steinberg MH: Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes. <i>Blood Rev.</i> 2007; <b>21</b>(1): 37–47. <a target=xrefwindow id=d25416e3200 href="http://www.ncbi.nlm.nih.gov/pubmed/17084951">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3203 href="https://doi.org/10.1016/j.blre.2006.07.001">Publisher Full Text </a> | <a target=xrefwindow id=d25416e3206 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2048670">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d25416e3215 class=n-a></a>Manwani D, Frenette PS: Vaso-occlusion in sickle cell disease: Pathophysiology and novel targeted therapies. <i>Hematology Am Soc Hematol Educ Program.</i> 2013; <b>2013</b>: 362–9. <a target=xrefwindow id=d25416e3223 href="http://www.ncbi.nlm.nih.gov/pubmed/24319205">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3226 href="https://doi.org/10.1182/asheducation-2013.1.362">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d25416e3235 class=n-a></a>Noubouossie D, Key NS, Ataga KI: Coagulation Abnormalities of Sickle Cell Disease: Relationship With Clinical Outcomes and the Effect of Disease Modifying Therapies. <i>Blood Rev.</i> 2016; <b>30</b>(4): 245–56. <a target=xrefwindow id=d25416e3243 href="http://www.ncbi.nlm.nih.gov/pubmed/26776344">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3246 href="https://doi.org/10.1016/j.blre.2015.12.003">Publisher Full Text </a> | <a target=xrefwindow id=d25416e3249 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4919240">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d25416e3258 class=n-a></a>Kato GJ, Piel FB, Reid CD, <i> et al.</i>: Sickle cell disease. <i>Nat Rev Dis Primers.</i> 2018; <b>4</b>: 18010. <a target=xrefwindow id=d25416e3269 href="http://www.ncbi.nlm.nih.gov/pubmed/29542687">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3272 href="https://doi.org/10.1038/nrdp.2018.10">Publisher Full Text </a></span><div class=note><a name=d25416e3274 class=n-a></a><p class=first id=d25416e3275><a target=xrefwindow href="https://facultyopinions.com/prime/732858103" id=d25416e3276>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d25416e3285 class=n-a></a>Charache S, Terrin ML, Moore RD, <i> et al.</i>: Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. <i>N Engl J Med.</i> 1995; <b>332</b>(20): 1317–22. <a target=xrefwindow id=d25416e3296 href="http://www.ncbi.nlm.nih.gov/pubmed/7715639">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3299 href="https://doi.org/10.1056/NEJM199505183322001">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d25416e3309 class=n-a></a><a target=xrefwindow id=d25416e3310><a target=xrefwindow id=d25416e3310 href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-l-glutamine-sickle-cell-disease"> https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-l-glutamine-sickle-cell-disease</a></a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d25416e3319 class=n-a></a><a target=xrefwindow id=d25416e3320><a target=xrefwindow id=d25416e3320 href="https://www.novartis.com/news/media-releases/new-novartis-medicine-adakveo-crizanlizumab-approved-fda-reduce-frequency-pain-crises-individuals-living-sickle-cell-disease"> https://www.novartis.com/news/media-releases/new-novartis-medicine-adakveo-crizanlizumab-approved-fda-reduce-frequency-pain-crises-individuals-living-sickle-cell-disease</a></a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d25416e3329 class=n-a></a><a target=xrefwindow id=d25416e3330><a target=xrefwindow id=d25416e3330 href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-voxelotor-sickle-cell-disease"> https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-voxelotor-sickle-cell-disease</a></a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d25416e3339 class=n-a></a>Eaton WA, Bunn HF: Treating sickle cell disease by targeting HbS polymerization. <i>Blood.</i> 2017; <b>129</b>(20): 2719–26. <a target=xrefwindow id=d25416e3347 href="http://www.ncbi.nlm.nih.gov/pubmed/28385699">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3350 href="https://doi.org/10.1182/blood-2017-02-765891">Publisher Full Text </a> | <a target=xrefwindow id=d25416e3353 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5437829">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d25416e3362 class=n-a></a>Platt OS, Brambilla DJ, Rosse WF, <i> et al.</i>: Mortality in Sickle Cell Disease. Life Expectancy and Risk Factors for Early Death. <i>N Engl J Med.</i> 1994; <b>330</b>(23): 1639–44. <a target=xrefwindow id=d25416e3373 href="http://www.ncbi.nlm.nih.gov/pubmed/7993409">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3376 href="https://doi.org/10.1056/NEJM199406093302303">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d25416e3385 class=n-a></a>Castro O, Brambilla DJ, Thorington B, <i> et al.</i>: The acute chest syndrome in sickle cell disease: Incidence and risk factors. The Cooperative Study of Sickle Cell Disease. <i>Blood.</i> 1994; <b>84</b>(2): 643–9. <a target=xrefwindow id=d25416e3396 href="http://www.ncbi.nlm.nih.gov/pubmed/7517723">PubMed Abstract </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d25416e3406 class=n-a></a>Mabaera R, West RJ, Conine SJ, <i> et al.</i>: A Cell Stress Signaling Model of Fetal Hemoglobin Induction: What Doesn't Kill Red Blood Cells May Make Them Stronger. <i>Exp Hematol.</i> 2008; <b>36</b>(9): 1057–72. <a target=xrefwindow id=d25416e3417 href="http://www.ncbi.nlm.nih.gov/pubmed/18718415">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3420 href="https://doi.org/10.1016/j.exphem.2008.06.014">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d25416e3429 class=n-a></a>Alcaín FJ, Löw H, Crane FL, <i> et al.</i>: Iron chelators hydroxyurea and bathophenanthroline disulfonate inhibit DNA synthesis by different pathways. <i>Biochem Mol Biol Int.</i> 1994; <b>34</b>(2): 273–9. <a target=xrefwindow id=d25416e3440 href="http://www.ncbi.nlm.nih.gov/pubmed/7849637">PubMed Abstract </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d25416e3449 class=n-a></a>Cokic VP, Smith RD, Beleslin-Cokic BB, <i> et al.</i>: Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. <i>J Clin Invest.</i> 2003; <b>111</b>(2): 231–9. <a target=xrefwindow id=d25416e3460 href="http://www.ncbi.nlm.nih.gov/pubmed/12531879">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3463 href="https://doi.org/10.1172/JCI16672">Publisher Full Text </a> | <a target=xrefwindow id=d25416e3467 href="http://www.ncbi.nlm.nih.gov/pmc/articles/151872">Free Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d25416e3476 class=n-a></a>Huang J, Yakubu M, Kim-Shapiro DB, <i> et al.</i>: Rat liver-mediated metabolism of hydroxyurea to nitric oxide. <i>Free Radic Biol Med.</i> 2006; <b>40</b>(9): 1675–81. <a target=xrefwindow id=d25416e3487 href="http://www.ncbi.nlm.nih.gov/pubmed/16632127">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3490 href="https://doi.org/10.1016/j.freeradbiomed.2006.01.002">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d25416e3499 class=n-a></a>McGann PT, Ware RE: Hydroxyurea for sickle cell anemia: What have we learned and what questions still remain? <i>Curr Opin Hematol.</i> 2011; <b>18</b>(3): 158–65. <a target=xrefwindow id=d25416e3507 href="http://www.ncbi.nlm.nih.gov/pubmed/21372708">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3510 href="https://doi.org/10.1097/MOH.0b013e32834521dd">Publisher Full Text </a> | <a target=xrefwindow id=d25416e3513 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3181131">Free Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d25416e3522 class=n-a></a>Bridges KR, Barabino GD, Brugnara C, <i> et al.</i>: A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. <i>Blood.</i> 1996; <b>88</b>(12): 4701–10. <a target=xrefwindow id=d25416e3533 href="http://www.ncbi.nlm.nih.gov/pubmed/8977264">PubMed Abstract </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d25416e3543 class=n-a></a>Hillery CA, Du MC, Wang WC, <i> et al.</i>: Hydroxyurea therapy decreases the <i>in vitro</i> adhesion of sickle erythrocytes to thrombospondin and laminin. <i>Br J Haematol.</i> 2000; <b>109</b>(2): 322–7. <a target=xrefwindow id=d25416e3557 href="http://www.ncbi.nlm.nih.gov/pubmed/10848818">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3561 href="https://doi.org/10.1046/j.1365-2141.2000.02040.x">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d25416e3570 class=n-a></a>Odievre MH, Bony V, Benkerrou M, <i> et al.</i>: Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease. <i>Haematologica.</i> 2008; <b>93</b>(4): 502–10. <a target=xrefwindow id=d25416e3581 href="http://www.ncbi.nlm.nih.gov/pubmed/18322255">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3584 href="https://doi.org/10.3324/haematol.12070">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d25416e3593 class=n-a></a>Laurance S, Lansiaux P, Pellay FX, <i> et al.</i>: Differential modulation of adhesion molecule expression by hydroxycarbamide in human endothelial cells from the micro- and macrocirculation: Potential implications in sickle cell disease vasoocclusive events. <i>Haematologica.</i> 2011; <b>96</b>(4): 534–42. <a target=xrefwindow id=d25416e3604 href="http://www.ncbi.nlm.nih.gov/pubmed/21228039">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3607 href="https://doi.org/10.3324/haematol.2010.026740">Publisher Full Text </a> | <a target=xrefwindow id=d25416e3611 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3069230">Free Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d25416e3620 class=n-a></a>Gladwin MT, Shelhamer JH, Ognibene FP, <i> et al.</i>: Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. <i>Br J Haematol.</i> 2002; <b>116</b>(2): 436–44. <a target=xrefwindow id=d25416e3631 href="http://www.ncbi.nlm.nih.gov/pubmed/11841449">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3634 href="https://doi.org/10.1046/j.1365-2141.2002.03274.x">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d25416e3643 class=n-a></a>Glover RE, Ivy ED, Orringer EP, <i> et al.</i>: Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea. <i>Mol Pharmacol.</i> 1999; <b>55</b>(6): 1006–10. <a target=xrefwindow id=d25416e3654 href="http://www.ncbi.nlm.nih.gov/pubmed/10347241">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3657 href="https://doi.org/10.1124/mol.55.6.1006">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d25416e3666 class=n-a></a>Wang WC, Ware RE, Miller ST, <i> et al.</i>: Hydroxycarbamide in Very Young Children With Sickle-Cell Anaemia: A Multicentre, Randomised, Controlled Trial (BABY HUG). <i>Lancet.</i> 2011; <b>377</b>(9778): 1663–72. <a target=xrefwindow id=d25416e3677 href="http://www.ncbi.nlm.nih.gov/pubmed/21571150">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3680 href="https://doi.org/10.1016/S0140-6736(11)60355-3">Publisher Full Text </a> | <a target=xrefwindow id=d25416e3684 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3133619">Free Full Text </a></span><div class=note><a name=d25416e3686 class=n-a></a><p class=first id=d25416e3687><a target=xrefwindow href="https://facultyopinions.com/prime/11575956" id=d25416e3688>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d25416e3698 class=n-a></a>Dehury S, Purohit P, Patel S, <i> et al.</i>: Low and Fixed Dose of Hydroxyurea Is Effective and Safe in Patients With HbSβ(+) Thalassemia With IVS1-5(G→C) Mutation. <i>Pediatr Blood Cancer.</i> 2015; <b>62</b>(6): 1017–23. <a target=xrefwindow id=d25416e3709 href="http://www.ncbi.nlm.nih.gov/pubmed/25546091">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3712 href="https://doi.org/10.1002/pbc.25391">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d25416e3721 class=n-a></a>Jain DL, Apte M, Colah R, <i> et al.</i>: Efficacy of Fixed Low Dose Hydroxyurea in Indian Children With Sickle Cell Anemia: <i>A Single Centre Experience</i>. <i>Indian Pediatr.</i> 2013; <b>50</b>(10): 929–33. <a target=xrefwindow id=d25416e3735 href="http://www.ncbi.nlm.nih.gov/pubmed/23798623">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3739 href="https://doi.org/10.1007/s13312-013-0264-0">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d25416e3748 class=n-a></a>Ware RE, Davis BR, Schultz WH, <i> et al.</i>: Hydroxycarbamide Versus Chronic Transfusion for Maintenance of Transcranial Doppler Flow Velocities in Children With Sickle Cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): A Multicentre, Open-Label, Phase 3, Non-Inferiority Trial. <i>Lancet.</i> 2016; <b>387</b>(10019): 661–70. <a target=xrefwindow id=d25416e3759 href="http://www.ncbi.nlm.nih.gov/pubmed/26670617">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3762 href="https://doi.org/10.1016/S0140-6736(15)01041-7">Publisher Full Text </a> | <a target=xrefwindow id=d25416e3766 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5724392">Free Full Text </a></span><div class=note><a name=d25416e3768 class=n-a></a><p class=first id=d25416e3769><a target=xrefwindow href="https://facultyopinions.com/prime/726014408" id=d25416e3770>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d25416e3779 class=n-a></a>Bartolucci P, Habibi A, Stehlé T, <i> et al.</i>: Six Months of Hydroxyurea Reduces Albuminuria in Patients With Sickle Cell Disease. <i>J Am Soc Nephrol.</i> 2016; <b>27</b>(6): 1847–53. <a target=xrefwindow id=d25416e3790 href="http://www.ncbi.nlm.nih.gov/pubmed/26586692">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3793 href="https://doi.org/10.1681/ASN.2014111126">Publisher Full Text </a> | <a target=xrefwindow id=d25416e3797 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4884099">Free Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d25416e3806 class=n-a></a>Lobo CLdC, Pinto JFC, Nascimento EM, <i> et al.</i>: The Effect of Hydroxcarbamide Therapy on Survival of Children With Sickle Cell Disease. <i>Br J Haematol.</i> 2013; <b>161</b>(6): 852–60. <a target=xrefwindow id=d25416e3817 href="http://www.ncbi.nlm.nih.gov/pubmed/23590693">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3820 href="https://doi.org/10.1111/bjh.12323">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d25416e3829 class=n-a></a>Steinberg MH, Barton F, Castro O, <i> et al.</i>: Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks and Benefits Up to 9 Years of Treatment. <i>JAMA.</i> 2003; <b>289</b>(13): 1645–51. <a target=xrefwindow id=d25416e3840 href="http://www.ncbi.nlm.nih.gov/pubmed/12672732">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3843 href="https://doi.org/10.1001/jama.289.13.1645">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d25416e3853 class=n-a></a>Steinberg MH, McCarthy WF, Castro O, <i> et al.</i>: The Risks and Benefits of Long-Term Use of Hydroxyurea in Sickle Cell Anemia: A 17.5 Year Follow-Up. <i>Am J Hematol.</i> 2010; <b>85</b>(6): 403–8. <a target=xrefwindow id=d25416e3864 href="http://www.ncbi.nlm.nih.gov/pubmed/20513116">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3867 href="https://doi.org/10.1002/ajh.21699">Publisher Full Text </a> | <a target=xrefwindow id=d25416e3871 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2879711">Free Full Text </a></span><div class=note><a name=d25416e3873 class=n-a></a><p class=first id=d25416e3874><a target=xrefwindow href="https://facultyopinions.com/prime/3621957" id=d25416e3875>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d25416e3884 class=n-a></a>Voskaridou E, Christoulas D, Bilalis A, <i> et al.</i>: The Effect of Prolonged Administration of Hydroxyurea on Morbidity and Mortality in Adult Patients With Sickle Cell Syndromes: Results of a 17-year, Single-Center Trial (LaSHS). <i>Blood.</i> 2010; <b>115</b>(12): 2354–63. <a target=xrefwindow id=d25416e3895 href="http://www.ncbi.nlm.nih.gov/pubmed/19903897">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3898 href="https://doi.org/10.1182/blood-2009-05-221333">Publisher Full Text </a></span><div class=note><a name=d25416e3900 class=n-a></a><p class=first id=d25416e3901><a target=xrefwindow href="https://facultyopinions.com/prime/3874956" id=d25416e3902>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d25416e3911 class=n-a></a>Ware RE: Optimizing Hydroxyurea Therapy for Sickle Cell Anemia. <i>Hematology Am Soc Hematol Educ Program.</i> 2015; <b>2015</b>: 436–43. <a target=xrefwindow id=d25416e3919 href="http://www.ncbi.nlm.nih.gov/pubmed/26637755">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3922 href="https://doi.org/10.1182/asheducation-2015.1.436">Publisher Full Text </a></span><div class=note><a name=d25416e3924 class=n-a></a><p class=first id=d25416e3925><a target=xrefwindow href="https://facultyopinions.com/prime/733801440" id=d25416e3926>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d25416e3934 class=n-a></a>McGann PT, Niss O, Dong M, <i> et al.</i>: Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. <i>Am J Hematol.</i> 2019; <b>94</b>(8): 871–9. <a target=xrefwindow id=d25416e3945 href="http://www.ncbi.nlm.nih.gov/pubmed/31106898">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3948 href="https://doi.org/10.1002/ajh.25510">Publisher Full Text </a> | <a target=xrefwindow id=d25416e3952 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6639795">Free Full Text </a></span><div class=note><a name=d25416e3954 class=n-a></a><p class=first id=d25416e3955><a target=xrefwindow href="https://facultyopinions.com/prime/735800235" id=d25416e3956>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d25416e3965 class=n-a></a>Estepp JH, Smeltzer MP, Kang G, <i> et al.</i>: A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy. <i>Am J Hematol.</i> 2017; <b>92</b>(12): 1333–9. <a target=xrefwindow id=d25416e3976 href="http://www.ncbi.nlm.nih.gov/pubmed/28913922">PubMed Abstract </a> | <a target=xrefwindow id=d25416e3979 href="https://doi.org/10.1002/ajh.24906">Publisher Full Text </a> | <a target=xrefwindow id=d25416e3983 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5675769">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d25416e3992 class=n-a></a>Hydroxyurea Optimization Through Precision Study (HOPS). <i>Clinical Trials.</i> 2020. <a target=xrefwindow id=d25416e3997 href="https://clinicaltrials.gov/ct2/show/NCT03789591">Reference Source</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d25416e4007 class=n-a></a>Nazon C, Sabo AN, Becker G, <i> et al.</i>: Optimizing Hydroxyurea Treatment for Sickle Cell Disease Patients: The Pharmacokinetic Approach. <i>J Clin Med.</i> 2019; <b>8</b>(10): 1701. <a target=xrefwindow id=d25416e4018 href="http://www.ncbi.nlm.nih.gov/pubmed/31623213">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4021 href="https://doi.org/10.3390/jcm8101701">Publisher Full Text </a> | <a target=xrefwindow id=d25416e4025 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6833033">Free Full Text </a></span><div class=note><a name=d25416e4027 class=n-a></a><p class=first id=d25416e4028><a target=xrefwindow href="https://facultyopinions.com/prime/736772015" id=d25416e4029>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d25416e4038 class=n-a></a>Saunthararajah Y, Molokie R, Saraf S, <i> et al.</i>: Clinical effectiveness of decitabine in severe sickle cell disease. <i>Br J Haematol.</i> 2008; <b>141</b>(1): 126–9. <a target=xrefwindow id=d25416e4049 href="http://www.ncbi.nlm.nih.gov/pubmed/18324975">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4052 href="https://doi.org/10.1111/j.1365-2141.2008.07027.x">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d25416e4061 class=n-a></a>Molokie R, Lavelle D, Gowhari M, <i> et al.</i>: Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study. <i>PLoS Med.</i> 2017; <b>14</b>(9): e1002382. <a target=xrefwindow id=d25416e4072 href="http://www.ncbi.nlm.nih.gov/pubmed/28880867">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4075 href="https://doi.org/10.1371/journal.pmed.1002382">Publisher Full Text </a> | <a target=xrefwindow id=d25416e4079 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5589090">Free Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d25416e4088 class=n-a></a>Atweh GF, Sutton M, Nassif I, <i> et al.</i>: Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. <i>Blood.</i> 1999; <b>93</b>(6): 1790–7. <a target=xrefwindow id=d25416e4099 href="http://www.ncbi.nlm.nih.gov/pubmed/10068649">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4102 href="https://doi.org/10.1182/blood.V93.6.1790.406k27_1790_1797">Publisher Full Text </a> | <a target=xrefwindow id=d25416e4106 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4269326">Free Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d25416e4115 class=n-a></a>Hebbel RP, Vercellotti GM, Pace BS, <i> et al.</i>: The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. <i>Blood.</i> 2010; <b>115</b>(12): 2483–90. <a target=xrefwindow id=d25416e4126 href="http://www.ncbi.nlm.nih.gov/pubmed/20053759">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4129 href="https://doi.org/10.1182/blood-2009-02-204990">Publisher Full Text </a> | <a target=xrefwindow id=d25416e4133 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2845902">Free Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d25416e4142 class=n-a></a>Ikuta T, Atweh G, Boosalis V, <i> et al.</i>: Cellular and Molecular Effects of a Pulse Butyrate Regimen and New Inducers of Globin Gene Expression and Hematopoiesis. <i>Ann N Y Acad Sci.</i> 1998; <b>850</b>: 87–99. <a target=xrefwindow id=d25416e4153 href="http://www.ncbi.nlm.nih.gov/pubmed/9668531">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4156 href="https://doi.org/10.1111/j.1749-6632.1998.tb10466.x">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d25416e4166 class=n-a></a>Kutlar A, Ataga K, Reid M, <i> et al.</i>: A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease. <i>Am J Hematol.</i> 2012; <b>87</b>(11): 1017–21. <a target=xrefwindow id=d25416e4177 href="http://www.ncbi.nlm.nih.gov/pubmed/22887019">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4180 href="https://doi.org/10.1002/ajh.23306">Publisher Full Text </a> | <a target=xrefwindow id=d25416e4184 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3904792">Free Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d25416e4193 class=n-a></a>Kutlar A, Reid ME, Inati A, <i> et al.</i>: A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. <i>Am J Hematol.</i> 2013; <b>88</b>(11): E255–E260. <a target=xrefwindow id=d25416e4204 href="http://www.ncbi.nlm.nih.gov/pubmed/23828223">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4207 href="https://doi.org/10.1002/ajh.23533">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d25416e4216 class=n-a></a>Okam MM, Esrick EB, Mandell E, <i> et al.</i>: Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea. <i>Blood.</i> 2015; <b>125</b>(33): 3668–9. <a target=xrefwindow id=d25416e4227 href="http://www.ncbi.nlm.nih.gov/pubmed/26045597">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4230 href="https://doi.org/10.1182/blood-2015-03-635391">Publisher Full Text </a> | <a target=xrefwindow id=d25416e4234 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4458806">Free Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d25416e4243 class=n-a></a>Reid ME, El Beshlawy A, Inati A, <i> et al.</i>: A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. <i>Am J Hematol.</i> 2014; <b>89</b>(7): 709–13. <a target=xrefwindow id=d25416e4254 href="http://www.ncbi.nlm.nih.gov/pubmed/24677033">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4257 href="https://doi.org/10.1002/ajh.23725">Publisher Full Text </a></span><div class=note><a name=d25416e4259 class=n-a></a><p class=first id=d25416e4260><a target=xrefwindow href="https://facultyopinions.com/prime/725527940" id=d25416e4261>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d25416e4270 class=n-a></a>Shearstone JR, Golonzhka O, Chonkar A, <i> et al.</i>: Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2. <i>PLoS One.</i> 2016; <b>11</b>: e0153767. <a target=xrefwindow id=d25416e4281 href="http://www.ncbi.nlm.nih.gov/pubmed/27073918">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4284 href="https://doi.org/10.1371/journal.pone.0153767">Publisher Full Text </a> | <a target=xrefwindow id=d25416e4288 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4830539">Free Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d25416e4297 class=n-a></a>Rivers A, Vaitkus K, Ruiz MA, <i> et al.</i>: RN-1, a potent and selective lysine-specific demethylase 1 inhibitor, increases γ-globin expression, F reticulocytes, and F cells in a sickle cell disease mouse model. <i>Exp Hematol.</i> 2015; <b>43</b>(7): 546–553.e3. <a target=xrefwindow id=d25416e4308 href="http://www.ncbi.nlm.nih.gov/pubmed/25931013">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4311 href="https://doi.org/10.1016/j.exphem.2015.04.005">Publisher Full Text </a> | <a target=xrefwindow id=d25416e4315 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6325640">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d25416e4325 class=n-a></a>Cui S, Lim KC, Shi L, <i> et al.</i>: The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice. <i>Blood.</i> 2015; <b>126</b>(3): 386–96. <a target=xrefwindow id=d25416e4336 href="http://www.ncbi.nlm.nih.gov/pubmed/26031919">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4339 href="https://doi.org/10.1182/blood-2015-02-626259">Publisher Full Text </a> | <a target=xrefwindow id=d25416e4343 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4504950">Free Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d25416e4352 class=n-a></a>Rivers A, Vaitkus K, Jagadeeswaran R, <i> et al.</i>: Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons. <i>Exp Hematol.</i> 2018; <b>67</b>: 60–64.e2. <a target=xrefwindow id=d25416e4363 href="http://www.ncbi.nlm.nih.gov/pubmed/30125603">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4366 href="https://doi.org/10.1016/j.exphem.2018.08.003">Publisher Full Text </a></span><div class=note><a name=d25416e4368 class=n-a></a><p class=first id=d25416e4369><a target=xrefwindow href="https://facultyopinions.com/prime/733859493" id=d25416e4370>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d25416e4379 class=n-a></a>Meiler SE, Wade M, Kutlar F, <i> et al.</i>: Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice. <i>Blood.</i> 2011; <b>118</b>(4): 1109–12. <a target=xrefwindow id=d25416e4390 href="http://www.ncbi.nlm.nih.gov/pubmed/21536862">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4393 href="https://doi.org/10.1182/blood-2010-11-319137">Publisher Full Text </a> | <a target=xrefwindow id=d25416e4397 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3148160">Free Full Text </a></span><div class=note><a name=d25416e4399 class=n-a></a><p class=first id=d25416e4400><a target=xrefwindow href="https://facultyopinions.com/prime/733859493" id=d25416e4401>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d25416e4410 class=n-a></a>Kutlar A, Swerdlow PS, Meiler SE, <i> et al.</i>: Pomalidomide In Sickle Cell Disease: Phase I Study Of a Novel Anti-Switching Agent. <i>Blood.</i> 2013; <b>122</b>(21): 777. <a target=xrefwindow id=d25416e4421 href="https://doi.org/10.1182/blood.V122.21.777.777">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d25416e4430 class=n-a></a>Zhang Y, Paikari A, Sumazin P, <i> et al.</i>: Metformin induces FOXO3-dependent fetal hemoglobin production in human primary erythroid cells. <i>Blood.</i> 2018; <b>132</b>(3): 321–33. <a target=xrefwindow id=d25416e4441 href="http://www.ncbi.nlm.nih.gov/pubmed/29884740">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4444 href="https://doi.org/10.1182/blood-2017-11-814335">Publisher Full Text </a> | <a target=xrefwindow id=d25416e4448 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6053951">Free Full Text </a></span><div class=note><a name=d25416e4450 class=n-a></a><p class=first id=d25416e4451><a target=xrefwindow href="https://facultyopinions.com/prime/733424423" id=d25416e4452>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d25416e4461 class=n-a></a>Krishnamoorthy S, Pace B, Gupta D, <i> et al.</i>: Dimethyl fumarate increases fetal hemoglobin, provides heme detoxification, and corrects anemia in sickle cell disease. <i>JCI Insight.</i> 2017; <b>2</b>(20): e96409. <a target=xrefwindow id=d25416e4472 href="http://www.ncbi.nlm.nih.gov/pubmed/29046485">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4475 href="https://doi.org/10.1172/jci.insight.96409">Publisher Full Text </a> | <a target=xrefwindow id=d25416e4479 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5846716">Free Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d25416e4489 class=n-a></a>Dai Y, Chen T, Ijaz H, <i> et al.</i>: <i>SIRT1</i> activates the expression of fetal hemoglobin genes. <i>Am J Hematol.</i> 2017; <b>92</b>(11): 1177–1186. <a target=xrefwindow id=d25416e4503 href="http://www.ncbi.nlm.nih.gov/pubmed/28776729">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4507 href="https://doi.org/10.1002/ajh.24879">Publisher Full Text </a> | <a target=xrefwindow id=d25416e4510 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5648331">Free Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d25416e4519 class=n-a></a>Oksenberg D, Dufu K, Patel MP, <i> et al.</i>: GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. <i>Br J Haematol.</i> 2016; <b>175</b>(1): 141–53. <a target=xrefwindow id=d25416e4530 href="http://www.ncbi.nlm.nih.gov/pubmed/27378309">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4533 href="https://doi.org/10.1111/bjh.14214">Publisher Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d25416e4542 class=n-a></a>Howard J, Hemmaway CJ, Telfer P, <i> et al.</i>: A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease. <i>Blood.</i> 2019; <b>133</b>(17): 1865–1875. <a target=xrefwindow id=d25416e4553 href="http://www.ncbi.nlm.nih.gov/pubmed/30655275">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4556 href="https://doi.org/10.1182/blood-2018-08-868893">Publisher Full Text </a> | <a target=xrefwindow id=d25416e4560 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6484388">Free Full Text </a></span><div class=note><a name=d25416e4562 class=n-a></a><p class=first id=d25416e4563><a target=xrefwindow href="https://facultyopinions.com/prime/734881066" id=d25416e4564>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d25416e4573 class=n-a></a>Dufu K, Patel M, Oksenberg D, <i> et al.</i>: GBT440 improves red blood cell deformability and reduces viscosity of sickle cell blood under deoxygenated conditions. <i>Clin Hemorheol Microcirc.</i> 2018; <b>70</b>(1): 95–105. <a target=xrefwindow id=d25416e4584 href="http://www.ncbi.nlm.nih.gov/pubmed/29660913">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4587 href="https://doi.org/10.3233/CH-170340">Publisher Full Text </a> | <a target=xrefwindow id=d25416e4591 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6996409">Free Full Text </a></span><div class=note><a name=d25416e4593 class=n-a></a><p class=first id=d25416e4594><a target=xrefwindow href="https://facultyopinions.com/prime/733293445" id=d25416e4595>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d25416e4604 class=n-a></a>Vichinsky E, Hoppe CC, Ataga KI, <i> et al.</i>: A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. <i>N Engl J Med.</i> 2019; <b>381</b>(6): 509–519. <a target=xrefwindow id=d25416e4615 href="http://www.ncbi.nlm.nih.gov/pubmed/31199090">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4618 href="https://doi.org/10.1056/NEJMoa1903212">Publisher Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d25416e4627 class=n-a></a>Kato GJ, Lawrence MP, Mendelsohn LG, <i> et al.</i>: Phase 1 Clinical Trial Of The Candidate Anti-Sickling Agent Aes-103 In Adults With Sickle Cell Anemia. <i>Blood.</i> 2013; <b>122</b>: 1009. <a target=xrefwindow id=d25416e4638 href="https://doi.org/10.1182/blood.V122.21.1009.1009">Publisher Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d25416e4648 class=n-a></a>Kalfa TA, Kuypers FA, Telen MJ, <i> et al.</i>: Phase 1 Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, in Healthy and Sickle Cell Disease Subjects. <i>Blood.</i> 2019; <b>134</b>(Supplement_1): 616. <a target=xrefwindow id=d25416e4659 href="https://doi.org/10.1182/blood-2019-121889">Publisher Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d25416e4668 class=n-a></a>Belcher JD, Young M, Chen C, <i> et al.</i>: MP4CO, a pegylated hemoglobin saturated with carbon monoxide, is a modulator of HO-1, inflammation, and vaso-occlusion in transgenic sickle mice. <i>Blood.</i> 2013; <b>122</b>(15): 2757–64. <a target=xrefwindow id=d25416e4679 href="http://www.ncbi.nlm.nih.gov/pubmed/23908468">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4682 href="https://doi.org/10.1182/blood-2013-02-486282">Publisher Full Text </a> | <a target=xrefwindow id=d25416e4686 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4067504">Free Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d25416e4695 class=n-a></a>Abuchowski A: SANGUINATE (PEGylated Carboxyhemoglobin Bovine): Mechanism of Action and Clinical Update. <i>Artif Organs.</i> 2017; <b>41</b>(4): 346–350. <a target=xrefwindow id=d25416e4703 href="http://www.ncbi.nlm.nih.gov/pubmed/28397407">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4706 href="https://doi.org/10.1111/aor.12934">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d25416e4715 class=n-a></a>Keipert PE: Clinical Evaluation of MP4CO: A Phase 1b Escalating-Dose, Safety and Tolerability Study in Stable Adult Patients with Sickle Cell Disease. <i>Adv Exp Med Biol.</i> 2016; <b>923</b>: 23–29. <a target=xrefwindow id=d25416e4723 href="http://www.ncbi.nlm.nih.gov/pubmed/27526120">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4726 href="https://doi.org/10.1007/978-3-319-38810-6_3">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d25416e4735 class=n-a></a>Misra H, Bainbridge J, Berryman J, <i> et al.</i>: A Phase Ib open label, randomized, safety study of SANGUINATE™ in patients with sickle cell anemia. <i>Rev Bras Hematol Hemoter.</i> 2017; <b>39</b>(1): 20–27. <a target=xrefwindow id=d25416e4746 href="http://www.ncbi.nlm.nih.gov/pubmed/28270341">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4749 href="https://doi.org/10.1016/j.bjhh.2016.08.004">Publisher Full Text </a> | <a target=xrefwindow id=d25416e4753 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5339363">Free Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d25416e4762 class=n-a></a>Sunshine HR, Hofrichter J, Eaton WA: Requirement for therapeutic inhibition of sickle haemoglobin gelation. <i>Nature.</i> 1978; <b>275</b>(5677): 238–40. <a target=xrefwindow id=d25416e4770 href="http://www.ncbi.nlm.nih.gov/pubmed/692700">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4773 href="https://doi.org/10.1038/275238a0">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d25416e4783 class=n-a></a>Ataga KI, Reid M, Ballas SK, <i> et al.</i>: Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: A phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043). <i>Br J Haematol.</i> 2011; <b>153</b>(1): 92–104. <a target=xrefwindow id=d25416e4794 href="http://www.ncbi.nlm.nih.gov/pubmed/21323872">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4797 href="https://doi.org/10.1111/j.1365-2141.2010.08520.x">Publisher Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d25416e4806 class=n-a></a>Ataga KI, Smith WR, de Castro LM, <i> et al.</i>: Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. <i>Blood.</i> 2008; <b>111</b>(8): 3991–7. <a target=xrefwindow id=d25416e4817 href="http://www.ncbi.nlm.nih.gov/pubmed/18192510">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4820 href="https://doi.org/10.1182/blood-2007-08-110098">Publisher Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d25416e4829 class=n-a></a>Brousseau DC, Scott JP, Badaki-Makun O, <i> et al.</i>: A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. <i>Blood.</i> 2015; <b>126</b>(14): 1651–7. <a target=xrefwindow id=d25416e4840 href="http://www.ncbi.nlm.nih.gov/pubmed/26232172">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4843 href="https://doi.org/10.1182/blood-2015-05-647107">Publisher Full Text </a> | <a target=xrefwindow id=d25416e4847 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4591790">Free Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d25416e4856 class=n-a></a>Goldman RD, Mounstephen W, Kirby-Allen M, <i> et al.</i>: Intravenous magnesium sulfate for vaso-occlusive episodes in sickle cell disease. <i>Pediatrics.</i> 2013; <b>132</b>(6): e1634–41. <a target=xrefwindow id=d25416e4867 href="http://www.ncbi.nlm.nih.gov/pubmed/24276838">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4870 href="https://doi.org/10.1542/peds.2013-2065">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d25416e4879 class=n-a></a>de Franceschi L, Bachir D, Galacteros F, <i> et al.</i>: Oral magnesium pidolate: Effects of long-term administration in patients with sickle cell disease. <i>Br J Haematol.</i> 2000; <b>108</b>(2): 284–9. <a target=xrefwindow id=d25416e4890 href="http://www.ncbi.nlm.nih.gov/pubmed/10691856">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4893 href="https://doi.org/10.1046/j.1365-2141.2000.01861.x">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d25416e4902 class=n-a></a>Swift R, Abdulmalik O, Chen Q, <i> et al.</i>: SCD-101: A New Anti-Sickling Drug Reduces Pain and Fatigue and Improves Red Blood Cell Shape in Peripheral Blood of Patients with Sickle Cell Disease. <i>Blood.</i> 2016; <b>128</b>(22): 121. <a target=xrefwindow id=d25416e4913 href="https://doi.org/10.1182/blood.V128.22.121.121">Publisher Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d25416e4923 class=n-a></a>Niihara Y, Smith WR, Stark CW: A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. <i>N Engl J Med.</i> 2018; <b>379</b>(19): 1880. <a target=xrefwindow id=d25416e4931 href="http://www.ncbi.nlm.nih.gov/pubmed/30403943">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4934 href="https://doi.org/10.1056/NEJMc1811050">Publisher Full Text </a></span><div class=note><a name=d25416e4936 class=n-a></a><p class=first id=d25416e4937><a target=xrefwindow href="https://facultyopinions.com/prime/734433889" id=d25416e4938>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d25416e4947 class=n-a></a>Nur E, Brandjes DP, Teerlink T, <i> et al.</i>: N-acetylcysteine reduces oxidative stress in sickle cell patients. <i>Ann Hematol.</i> 2012; <b>91</b>(7): 1097–105. <a target=xrefwindow id=d25416e4958 href="http://www.ncbi.nlm.nih.gov/pubmed/22318468">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4961 href="https://doi.org/10.1007/s00277-011-1404-z">Publisher Full Text </a> | <a target=xrefwindow id=d25416e4965 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3368118">Free Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d25416e4974 class=n-a></a>Sins JWR, Fijnvandraat K, Rijneveld AW, <i> et al.</i>: Effect of N-acetylcysteine on pain in daily life in patients with sickle cell disease: A randomised clinical trial. <i>Br J Haematol.</i> 2018; <b>182</b>(3): 444–8. <a target=xrefwindow id=d25416e4985 href="http://www.ncbi.nlm.nih.gov/pubmed/28643376">PubMed Abstract </a> | <a target=xrefwindow id=d25416e4988 href="https://doi.org/10.1111/bjh.14809">Publisher Full Text </a></span><div class=note><a name=d25416e4990 class=n-a></a><p class=first id=d25416e4991><a target=xrefwindow href="https://facultyopinions.com/prime/738070680" id=d25416e4992>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d25416e5001 class=n-a></a>Ataga KI, Kutlar A, Kanter J, <i> et al.</i>: Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. <i>N Engl J Med.</i> 2017; <b>376</b>(5): 429–39. <a target=xrefwindow id=d25416e5012 href="http://www.ncbi.nlm.nih.gov/pubmed/27959701">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5015 href="https://doi.org/10.1056/NEJMoa1611770">Publisher Full Text </a> | <a target=xrefwindow id=d25416e5019 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5481200">Free Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d25416e5028 class=n-a></a>Orringer EP, Casella JF, Ataga KI, <i> et al.</i>: Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial. <i>JAMA.</i> 2001; <b>286</b>(17): 2099–106. <a target=xrefwindow id=d25416e5039 href="http://www.ncbi.nlm.nih.gov/pubmed/11694150">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5042 href="https://doi.org/10.1001/jama.286.17.2099">Publisher Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d25416e5051 class=n-a></a><a target=xrefwindow id=d25416e5052><a target=xrefwindow id=d25416e5052 href="https://www.prnewswire.com/news-releases/mast-therapeutics-reports-top-line-results-from-phase-3-study-in-sickle-cell-disease-300331289.html"> https://www.prnewswire.com/news-releases/mast-therapeutics-reports-top-line-results-from-phase-3-study-in-sickle-cell-disease-300331289.html</a></a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d25416e5062 class=n-a></a>Chang J, Patton JT, Sarkar A, <i> et al.</i>: GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice. <i>Blood.</i> 2010; <b>116</b>(10): 1779–86. <a target=xrefwindow id=d25416e5073 href="http://www.ncbi.nlm.nih.gov/pubmed/20508165">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5076 href="https://doi.org/10.1182/blood-2009-12-260513">Publisher Full Text </a> | <a target=xrefwindow id=d25416e5080 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2947397">Free Full Text </a></span><div class=note><a name=d25416e5082 class=n-a></a><p class=first id=d25416e5083><a target=xrefwindow href="https://facultyopinions.com/prime/720029239" id=d25416e5084>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d25416e5093 class=n-a></a>Telen MJ, Wun T, McCavit TL, <i> et al.</i>: Randomized phase 2 study of GMI-1070 in SCD: Reduction in time to resolution of vaso-occlusive events and decreased opioid use. <i>Blood.</i> 2015; <b>125</b>(17): 2656–64. <a target=xrefwindow id=d25416e5104 href="http://www.ncbi.nlm.nih.gov/pubmed/25733584">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5107 href="https://doi.org/10.1182/blood-2014-06-583351">Publisher Full Text </a> | <a target=xrefwindow id=d25416e5111 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4408290">Free Full Text </a></span><div class=note><a name=d25416e5113 class=n-a></a><p class=first id=d25416e5114><a target=xrefwindow href="https://facultyopinions.com/prime/725373625" id=d25416e5115>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d25416e5124 class=n-a></a><a target=xrefwindow id=d25416e5125><a target=xrefwindow id=d25416e5125 href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_phase_3_top_line_results_for_rivipansel_in_patients_with_sickle_cell_disease_experiencing_a_vaso_occlusive_crisis"> https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_phase_3_top_line_results_for_rivipansel_in_patients_with_sickle_cell_disease_experiencing_a_vaso_occlusive_crisis</a></a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d25416e5134 class=n-a></a>Matsui NM, Varki A, Embury SH: Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. <i>Blood.</i> 2002; <b>100</b>(10): 3790–6. <a target=xrefwindow id=d25416e5142 href="http://www.ncbi.nlm.nih.gov/pubmed/12393591">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5145 href="https://doi.org/10.1182/blood-2002-02-0626">Publisher Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d25416e5154 class=n-a></a>Embury SH, Matsui NM, Ramanujam S, <i> et al.</i>: The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes <i>in vivo</i>. <i>Blood.</i> 2004; <b>104</b>(10): 3378–85. <a target=xrefwindow id=d25416e5168 href="http://www.ncbi.nlm.nih.gov/pubmed/15271798">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5172 href="https://doi.org/10.1182/blood-2004-02-0713">Publisher Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d25416e5181 class=n-a></a>Qari MH, Aljaouni SK, Alardawi MS, <i> et al.</i>: Reduction of Painful Vaso-occlusive Crisis of Sickle Cell Anaemia by Tinzaparin in a Double-blind Randomized Trial. <i>Thromb Haemost.</i> 2017; <b>98</b>(02): 392–6. <a target=xrefwindow id=d25416e5192 href="http://www.ncbi.nlm.nih.gov/pubmed/17721622">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5195 href="https://doi.org/10.1160/Th06-12-0718">Publisher Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d25416e5205 class=n-a></a>Telen MJ, Batchvarova M, Shan S, <i> et al.</i>: Sevuparin Binds to Multiple Adhesive Ligands and Reduces Sickle Red Blood Cell-induced Vaso-occlusion. <i>Br J Haematol.</i> 2016; <b>175</b>: 935–48. <a target=xrefwindow id=d25416e5216 href="http://www.ncbi.nlm.nih.gov/pubmed/27549988">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5219 href="https://doi.org/10.1111/bjh.14303">Publisher Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d25416e5228 class=n-a></a>Biemond BJ, Tombak A, Kilinc Y, <i> et al.</i>: Efficacy and Safety of Sevuparin, a Novel Non-Anti-Coagulant Heparinoid, in Patients with Acute Painful Vaso-Occlusive Crisis; A Global, Multicenter Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial (TVOC01). <i>Blood.</i> 2019; <b>134</b>(supp 1): 614. <a target=xrefwindow id=d25416e5239 href="https://doi.org/10.1182/blood-2019-124653">Publisher Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d25416e5248 class=n-a></a>Jang JE, Hidalgo A, Frenette PS: Intravenous immunoglobulins modulate neutrophil activation and vascular injury through FcγRIII and SHP-1. <i>Circ Res.</i> 2012; <b>110</b>(8): 1057–66. <a target=xrefwindow id=d25416e5256 href="http://www.ncbi.nlm.nih.gov/pubmed/22415018">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5259 href="https://doi.org/10.1161/CIRCRESAHA.112.266411">Publisher Full Text </a> | <a target=xrefwindow id=d25416e5262 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3351009">Free Full Text </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d25416e5271 class=n-a></a>Manwani D, Chen G, Carullo V, <i> et al.</i>: Single-dose Intravenous Gammaglobulin Can Stabilize Neutrophil Mac-1 Activation in Sickle Cell Pain Crisis. <i>Am J Hematol.</i> 2015; <b>90</b>(5): 381–5. <a target=xrefwindow id=d25416e5282 href="http://www.ncbi.nlm.nih.gov/pubmed/25616042">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5285 href="https://doi.org/10.1002/ajh.23956">Publisher Full Text </a> | <a target=xrefwindow id=d25416e5289 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4409477">Free Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d25416e5298 class=n-a></a>Griffin TC, McIntire D, Buchanan GR: High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. <i>N Engl J Med.</i> 1994; <b>330</b>(11): 733–7. <a target=xrefwindow id=d25416e5306 href="http://www.ncbi.nlm.nih.gov/pubmed/8107739">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5309 href="https://doi.org/10.1056/NEJM199403173301101">Publisher Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d25416e5318 class=n-a></a>Bernini JC, Rogers ZR, Sandler ES, <i> et al.</i>: Beneficial Effect of Intravenous Dexamethasone in Children With Mild to Moderately Severe Acute Chest Syndrome Complicating Sickle Cell Disease. <i>Blood.</i> 1998; <b>92</b>(9): 3082–9. <a target=xrefwindow id=d25416e5329 href="http://www.ncbi.nlm.nih.gov/pubmed/9787142">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5332 href="https://doi.org/10.1182/blood.V92.9.3082">Publisher Full Text </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d25416e5342 class=n-a></a>Leonard A, Godiwala N, Herrera N, <i> et al.</i>: Early Initiation of Inhaled Corticosteroids does not Decrease Acute Chest Syndrome Morbidity in Pediatric Patients with Sickle Cell Disease. <i>Blood Cells Mol Dis.</i> 2018; <b>71</b>: 55–62. <a target=xrefwindow id=d25416e5353 href="http://www.ncbi.nlm.nih.gov/pubmed/29550053">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5356 href="https://doi.org/10.1016/j.bcmd.2018.03.001">Publisher Full Text </a></span><div class=note><a name=d25416e5358 class=n-a></a><p class=first id=d25416e5359><a target=xrefwindow href="https://facultyopinions.com/prime/732905476" id=d25416e5360>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a name=d25416e5369 class=n-a></a>Glassberg J, Minnitti C, Cromwell C, <i> et al.</i>: Inhaled Steroids Reduce Pain and sVCAM Levels in Individuals with Sickle Cell Disease: A Triple-blind, Randomized trial. <i>Am J Hematol.</i> 2017; <b>92</b>: 622–31. <a target=xrefwindow id=d25416e5380 href="http://www.ncbi.nlm.nih.gov/pubmed/28370266">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5383 href="https://doi.org/10.1002/ajh.24742">Publisher Full Text </a> | <a target=xrefwindow id=d25416e5387 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5484635">Free Full Text </a></span><div class=note><a name=d25416e5389 class=n-a></a><p class=first id=d25416e5390><a target=xrefwindow href="https://facultyopinions.com/prime/727473146" id=d25416e5391>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a name=d25416e5400 class=n-a></a>Wallace KL, Linden J: Adenosine A2A Receptors Induced on iNKT and NK Cells Reduce Pulmonary Inflammation and Injury in Mice with Sickle Cell Disease. <i>Blood.</i> 2010; <b>116</b>: 5010–20. <a target=xrefwindow id=d25416e5408 href="http://www.ncbi.nlm.nih.gov/pubmed/20798237">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5411 href="https://doi.org/10.1182/blood-2010-06-290643">Publisher Full Text </a> | <a target=xrefwindow id=d25416e5414 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3012594">Free Full Text </a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d25416e5423 class=n-a></a>Field JJ, Lin G, Okam MM, <i> et al.</i>: Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. <i>Blood.</i> 2013; <b>121</b>(17): 3329–34. <a target=xrefwindow id=d25416e5434 href="http://www.ncbi.nlm.nih.gov/pubmed/23377438">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5437 href="https://doi.org/10.1182/blood-2012-11-465963">Publisher Full Text </a> | <a target=xrefwindow id=d25416e5441 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3637009">Free Full Text </a></span><div class=note><a name=d25416e5443 class=n-a></a><p class=first id=d25416e5444><a target=xrefwindow href="https://facultyopinions.com/prime/717985161" id=d25416e5445>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d25416e5454 class=n-a></a>Field JJ, Majerus E, Gordeuk VR, <i> et al.</i>: Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease. <i>Blood Adv.</i> 2017; <b>1</b>(20): 1645–9. <a target=xrefwindow id=d25416e5465 href="http://www.ncbi.nlm.nih.gov/pubmed/29296811">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5468 href="https://doi.org/10.1182/bloodadvances.2017009613">Publisher Full Text </a> | <a target=xrefwindow id=d25416e5472 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5728341">Free Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d25416e5481 class=n-a></a>Field JJ, Majerus E, Ataga KI, <i> et al.</i>: NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease. <i>PLoS One.</i> 2017; <b>12</b>(2): e0171067. <a target=xrefwindow id=d25416e5492 href="http://www.ncbi.nlm.nih.gov/pubmed/28152086">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5495 href="https://doi.org/10.1371/journal.pone.0171067">Publisher Full Text </a> | <a target=xrefwindow id=d25416e5499 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5289534">Free Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d25416e5509 class=n-a></a>Hoppe C, Kuypers F, Larkin S, <i> et al.</i>: A pilot study of the short-term use of simvastatin in sickle cell disease: Effects on markers of vascular dysfunction. <i>Br J Haematol.</i> 2011; <b>153</b>(5): 655–63. <a target=xrefwindow id=d25416e5520 href="http://www.ncbi.nlm.nih.gov/pubmed/21477202">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5523 href="https://doi.org/10.1111/j.1365-2141.2010.08480.x">Publisher Full Text </a> | <a target=xrefwindow id=d25416e5527 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3601917">Free Full Text </a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d25416e5536 class=n-a></a>Hoppe C, Jacob E, Styles L, <i> et al.</i>: Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: A pilot efficacy trial. <i>Br J Haematol.</i> 2017; <b>177</b>(4): 620–9. <a target=xrefwindow id=d25416e5547 href="http://www.ncbi.nlm.nih.gov/pubmed/28369718">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5550 href="https://doi.org/10.1111/bjh.14580">Publisher Full Text </a> | <a target=xrefwindow id=d25416e5554 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5435522">Free Full Text </a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d25416e5563 class=n-a></a>Ataga KI, Wichlan D, Elsherif L, <i> et al.</i>: A pilot study of the effect of atorvastatin on endothelial function and albuminuria in sickle cell disease. <i>Am J Hematol.</i> 2019; <b>94</b>(11): E299–E301. <a target=xrefwindow id=d25416e5574 href="http://www.ncbi.nlm.nih.gov/pubmed/31407373">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5577 href="https://doi.org/10.1002/ajh.25614">Publisher Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d25416e5586 class=n-a></a>Daak AA, Ghebremeskel K, Hassan Z, <i> et al.</i>: Effect of omega-3 (n-3) fatty acid supplementation in patients with sickle cell anemia: Randomized, double-blind, placebo-controlled trial. <i>Am J Clin Nutr.</i> 2013; <b>97</b>(1): 37–44. <a target=xrefwindow id=d25416e5597 href="http://www.ncbi.nlm.nih.gov/pubmed/23193009">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5600 href="https://doi.org/10.3945/ajcn.112.036319">Publisher Full Text </a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a name=d25416e5609 class=n-a></a>Daak AA, Dampier CD, Fuh B, <i> et al.</i>: Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial). <i>Blood Adv.</i> 2018; <b>2</b>(15): 1969–79. <a target=xrefwindow id=d25416e5620 href="http://www.ncbi.nlm.nih.gov/pubmed/30097463">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5623 href="https://doi.org/10.1182/bloodadvances.2018021444">Publisher Full Text </a> | <a target=xrefwindow id=d25416e5627 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6093734">Free Full Text </a></span><div class=note><a name=d25416e5629 class=n-a></a><p class=first id=d25416e5630><a target=xrefwindow href="https://facultyopinions.com/prime/733827485" id=d25416e5631>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a name=d25416e5640 class=n-a></a>Rees DC, Kilinc Y, Unal S, <i> et al.</i>: Double-Blind, Randomized Study of Canakinumab Treatment in Pediatric and Young Adult Patients with Sickle Cell Anemia. <i>Blood.</i> 2019; <b>134</b>: 615. <a target=xrefwindow id=d25416e5651 href="https://doi.org/10.1182/blood-2019-123355">Publisher Full Text </a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d25416e5661 class=n-a></a>Gavins FNE, Russell J, Senchenkova EL, <i> et al.</i>: Mechanisms of enhanced thrombus formation in cerebral microvessels of mice expressing hemoglobin-S. <i>Blood.</i> 2011; <b>117</b>(15): 4125–33. <a target=xrefwindow id=d25416e5672 href="http://www.ncbi.nlm.nih.gov/pubmed/21304105">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5675 href="https://doi.org/10.1182/blood-2010-08-301366">Publisher Full Text </a> | <a target=xrefwindow id=d25416e5679 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3087535">Free Full Text </a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a name=d25416e5688 class=n-a></a>Chantrathammachart P, Mackman N, Sparkenbaugh E, <i> et al.</i>: Tissue Factor Promotes Activation of Coagulation and Inflammation in a Mouse Model of Sickle Cell Disease. <i>Blood.</i> 2012; <b>120</b>(3): 636–46. <a target=xrefwindow id=d25416e5699 href="http://www.ncbi.nlm.nih.gov/pubmed/22661702">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5702 href="https://doi.org/10.1182/blood-2012-04-424143">Publisher Full Text </a> | <a target=xrefwindow id=d25416e5706 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3401215">Free Full Text </a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a name=d25416e5715 class=n-a></a>Arumugam PI, Mullins ES, Shanmukhappa SK, <i> et al.</i>: Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice. <i>Blood.</i> 2015; <b>126</b>(15): 1844–55. <a target=xrefwindow id=d25416e5726 href="http://www.ncbi.nlm.nih.gov/pubmed/26286849">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5729 href="https://doi.org/10.1182/blood-2015-01-625707">Publisher Full Text </a> | <a target=xrefwindow id=d25416e5733 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4600020">Free Full Text </a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a name=d25416e5742 class=n-a></a>Ataga KI, Key NS: Hypercoagulability in Sickle Cell Disease: New Approaches to an Old Problem. <i>Hematology Am Soc Hematol Educ Program.</i> 2007; <b>2007</b>: 91–6. <a target=xrefwindow id=d25416e5750 href="http://www.ncbi.nlm.nih.gov/pubmed/18024615">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5753 href="https://doi.org/10.1182/asheducation-2007.1.91">Publisher Full Text </a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a name=d25416e5762 class=n-a></a>Pakbaz Z, Wun T: Role of the Hemostatic System on Sickle Cell Disease Pathophysiology and Potential Therapeutics. <i>Hematol Oncol Clin North Am.</i> 2014; <b>28</b>(2): 355–74. <a target=xrefwindow id=d25416e5770 href="http://www.ncbi.nlm.nih.gov/pubmed/24589271">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5773 href="https://doi.org/10.1016/j.hoc.2013.11.011">Publisher Full Text </a> | <a target=xrefwindow id=d25416e5776 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3984936">Free Full Text </a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a name=d25416e5785 class=n-a></a>Greenberg J, Ohene-Frempong K, Halus J, <i> et al.</i>: Trial of Low Doses of Aspirin as Prophylaxis in Sickle Cell Disease. <i>J Pediatr.</i> 1983; <b>102</b>(5): 781–4. <a target=xrefwindow id=d25416e5796 href="http://www.ncbi.nlm.nih.gov/pubmed/6842340">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5799 href="https://doi.org/10.1016/s0022-3476(83)80258-3">Publisher Full Text </a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a name=d25416e5809 class=n-a></a>Osamo NO, Photiades DP, Famodu AA: Therapeutic effect of aspirin in sickle cell anaemia. <i>Acta Haematol.</i> 1981; <b>66</b>(2): 102–7. <a target=xrefwindow id=d25416e5817 href="http://www.ncbi.nlm.nih.gov/pubmed/6794308">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5820 href="https://doi.org/10.1159/000207105">Publisher Full Text </a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a name=d25416e5829 class=n-a></a>Zago MA, Costa FF, Ismael SJ, <i> et al.</i>: Treatment of Sickle Cell Diseases With Aspirin. <i>Acta Haematol.</i> 1984; <b>72</b>(1): 61–4. <a target=xrefwindow id=d25416e5840 href="http://www.ncbi.nlm.nih.gov/pubmed/6433636">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5843 href="https://doi.org/10.1159/000206360">Publisher Full Text </a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a name=d25416e5852 class=n-a></a>Desai PC, Brittain JE, Jones SK, <i> et al.</i>: A Pilot Study of Eptifibatide for Treatment of Acute Pain Episodes in Sickle Cell Disease. <i>Thromb Res.</i> 2013; <b>132</b>(3): 341–5. <a target=xrefwindow id=d25416e5863 href="http://www.ncbi.nlm.nih.gov/pubmed/23973010">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5866 href="https://doi.org/10.1016/j.thromres.2013.08.002">Publisher Full Text </a> | <a target=xrefwindow id=d25416e5870 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3791139">Free Full Text </a></span><div class=note><a name=d25416e5872 class=n-a></a><p class=first id=d25416e5873><a target=xrefwindow href="https://facultyopinions.com/prime/718086446" id=d25416e5874>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a name=d25416e5883 class=n-a></a>Cabannes R, Lonsdorfer J, Castaigne JP, <i> et al.</i>: Clinical and Biological Double-Blind-Study of Ticlopidine in Preventive Treatment of Sickle-Cell Disease Crises. <i>Agents Actions Suppl.</i> 1984; <b>15</b>: 199–212. <a target=xrefwindow id=d25416e5894 href="http://www.ncbi.nlm.nih.gov/pubmed/6385647">PubMed Abstract </a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a name=d25416e5903 class=n-a></a>Heeney MM, Hoppe CC, Abboud MR, <i> et al.</i>: A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. <i>N Engl J Med.</i> 2016; <b>374</b>(7): 625–35. <a target=xrefwindow id=d25416e5914 href="http://www.ncbi.nlm.nih.gov/pubmed/26644172">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5917 href="https://doi.org/10.1056/NEJMoa1512021">Publisher Full Text </a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a name=d25416e5926 class=n-a></a>Hsu LL, Sarnaik S, Williams S, <i> et al.</i>: A Dose-Ranging Study of Ticagrelor in Children Aged 3-17 Years With Sickle Cell Disease: A 2-part Phase 2 Study. <i>Am J Hematol.</i> 2018; <b>93</b>(12): 1493–500. <a target=xrefwindow id=d25416e5937 href="http://www.ncbi.nlm.nih.gov/pubmed/30187935">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5940 href="https://doi.org/10.1002/ajh.25273">Publisher Full Text </a> | <a target=xrefwindow id=d25416e5944 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6282821">Free Full Text </a></span><div class=note><a name=d25416e5946 class=n-a></a><p class=first id=d25416e5947><a target=xrefwindow href="https://facultyopinions.com/prime/733956895" id=d25416e5948>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a name=d25416e5958 class=n-a></a>Kanter J, Abboud MR, Kaya B, <i> et al.</i>: Ticagrelor Does Not Impact Patient-Reported Pain in Young Adults With Sickle Cell Disease: A Multicentre, Randomised Phase IIb Study. <i>Br J Haematol.</i> 2019; <b>184</b>(2): 269–78. <a target=xrefwindow id=d25416e5969 href="http://www.ncbi.nlm.nih.gov/pubmed/30443999">PubMed Abstract </a> | <a target=xrefwindow id=d25416e5972 href="https://doi.org/10.1111/bjh.15646">Publisher Full Text </a> | <a target=xrefwindow id=d25416e5976 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6587797">Free Full Text </a></span><div class=note><a name=d25416e5978 class=n-a></a><p class=first id=d25416e5979><a target=xrefwindow href="https://facultyopinions.com/prime/734452666" id=d25416e5980>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a name=d25416e5989 class=n-a></a>Heeney MM, Abboud MR, Amilon C, <i> et al.</i>: Ticagrelor Versus Placebo for the Reduction of Vaso-Occlusive Crises in Pediatric Sickle Cell Disease: Rationale and Design of a Randomized, Double-Blind, Parallel-Group, Multicenter Phase 3 Study (HESTIA3). <i>Contemp Clin Trials.</i> 2019; <b>85</b>: 105835. <a target=xrefwindow id=d25416e6000 href="http://www.ncbi.nlm.nih.gov/pubmed/31446143">PubMed Abstract </a> | <a target=xrefwindow id=d25416e6003 href="https://doi.org/10.1016/j.cct.2019.105835">Publisher Full Text </a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a name=d25416e6012 class=n-a></a>Kato GJ, Steinberg MH, Gladwin MT: Intravascular Hemolysis and the Pathophysiology of Sickle Cell Disease. <i>J Clin Invest.</i> 2017; <b>127</b>(3): 750–60. <a target=xrefwindow id=d25416e6020 href="http://www.ncbi.nlm.nih.gov/pubmed/28248201">PubMed Abstract </a> | <a target=xrefwindow id=d25416e6023 href="https://doi.org/10.1172/JCI89741">Publisher Full Text </a> | <a target=xrefwindow id=d25416e6026 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5330745">Free Full Text </a></span></li><li><a name=ref-135 class=n-a></a><span class=label>135. </span>&nbsp;<span class=citation><a name=d25416e6035 class=n-a></a>Gladwin MT, Kato GJ, Weiner D, <i> et al.</i>: Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis: A Randomized Controlled Trial. <i>JAMA.</i> 2011; <b>305</b>(9): 893–902. <a target=xrefwindow id=d25416e6046 href="http://www.ncbi.nlm.nih.gov/pubmed/21364138">PubMed Abstract </a> | <a target=xrefwindow id=d25416e6049 href="https://doi.org/10.1001/jama.2011.235">Publisher Full Text </a> | <a target=xrefwindow id=d25416e6053 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3403835">Free Full Text </a></span></li><li><a name=ref-136 class=n-a></a><span class=label>136. </span>&nbsp;<span class=citation><a name=d25416e6062 class=n-a></a>Maitre B, Djibre M, Katsahian S, <i> et al.</i>: Inhaled Nitric Oxide for Acute Chest Syndrome in Adult Sickle Cell Patients: A Randomized Controlled Study. <i>Intensive Care Med.</i> 2015; <b>41</b>(12): 2121–9. <a target=xrefwindow id=d25416e6073 href="http://www.ncbi.nlm.nih.gov/pubmed/26431718">PubMed Abstract </a> | <a target=xrefwindow id=d25416e6076 href="https://doi.org/10.1007/s00134-015-4060-2">Publisher Full Text </a></span></li><li><a name=ref-137 class=n-a></a><span class=label>137. </span>&nbsp;<span class=citation><a name=d25416e6085 class=n-a></a>Morris CR, Kuypers FA, Lavrisha L, <i> et al.</i>: A Randomized, Placebo-Controlled Trial of Arginine Therapy for the Treatment of Children With Sickle Cell Disease Hospitalized With Vaso-Occlusive Pain Episodes. <i>Haematologica.</i> 2013; <b>98</b>(9): 1375–82. <a target=xrefwindow id=d25416e6096 href="http://www.ncbi.nlm.nih.gov/pubmed/23645695">PubMed Abstract </a> | <a target=xrefwindow id=d25416e6099 href="https://doi.org/10.3324/haematol.2013.086637">Publisher Full Text </a> | <a target=xrefwindow id=d25416e6103 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3762093">Free Full Text </a></span><div class=note><a name=d25416e6105 class=n-a></a><p class=first id=d25416e6106><a target=xrefwindow href="https://facultyopinions.com/prime/718016103" id=d25416e6107>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-138 class=n-a></a><span class=label>138. </span>&nbsp;<span class=citation><a name=d25416e6117 class=n-a></a>Eleutério RMN, Nascimento FO, Araújo TG, <i> et al.</i>: Double-Blind Clinical Trial of Arginine Supplementation in the Treatment of Adult Patients With Sickle Cell Anaemia. <i>Adv Hematol.</i> 2019; <b>2019</b>: 4397150. <a target=xrefwindow id=d25416e6128 href="http://www.ncbi.nlm.nih.gov/pubmed/30853991">PubMed Abstract </a> | <a target=xrefwindow id=d25416e6131 href="https://doi.org/10.1155/2019/4397150">Publisher Full Text </a> | <a target=xrefwindow id=d25416e6135 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6378076">Free Full Text </a></span><div class=note><a name=d25416e6137 class=n-a></a><p class=first id=d25416e6138><a target=xrefwindow href="https://facultyopinions.com/prime/735306606" id=d25416e6139>Faculty Opinions Recommendation</a></p></div></li><li><a name=ref-139 class=n-a></a><span class=label>139. </span>&nbsp;<span class=citation><a name=d25416e6148 class=n-a></a>Machado RF, Barst RJ, Yovetich NA, <i> et al.</i>: Hospitalization for Pain in Patients With Sickle Cell Disease Treated With Sildenafil for Elevated TRV and Low Exercise Capacity. <i>Blood.</i> 2011; <b>118</b>(4): 855–64. <a target=xrefwindow id=d25416e6159 href="http://www.ncbi.nlm.nih.gov/pubmed/21527519">PubMed Abstract </a> | <a target=xrefwindow id=d25416e6162 href="https://doi.org/10.1182/blood-2010-09-306167">Publisher Full Text </a> | <a target=xrefwindow id=d25416e6166 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3148167">Free Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 11 Jun 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-592/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-592/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA<br/> <sup>2</sup> Center for Sickle Cell Disease, University of Tennessee Health Science Center, Memphis, TN, USA<br/> <p> <div class=margin-bottom> Parul Rai <br/> <span>Roles: </span> Investigation, Writing – Original Draft Preparation </div> <div class=margin-bottom> Kenneth I. Ataga <br/> <span>Roles: </span> Conceptualization, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/9-592/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 11 Jun 2020, 9:592 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.22433.1">https://doi.org/10.12688/f1000research.22433.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2020 Rai P and Ataga KI. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=24752 data-id=22433 data-downloads="" data-views="" data-scholar="10.12688/f1000research.22433.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/9-592/v1/pdf?article_uuid=425cc9df-2d8a-413e-8906-cd62ac08d2a8" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.22433.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Rai P and Ataga KI. Drug Therapies for the Management of Sickle Cell Disease [version 1; peer review: 1 approved] <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):592 (<a href="https://doi.org/10.12688/f1000research.22433.1" target=_blank>https://doi.org/10.12688/f1000research.22433.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=22433 id=mobile-track-article-signin-22433 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/22433?target=/articles/9-592/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=24752 /> <input name=articleId type=hidden value=22433 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Daniel E. Bauer</strong>, Division of Hematology/Oncology, Boston Children's Hospital, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, USA; Department of Pediatrics, Harvard Medical School, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Yogen Saunthararajah</strong>, Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> YS has patents, owns equity in, and serves on the board of a company EpiDestiny that is developing drug therapy for sickle cell disease. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 11 Jun 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-592/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-592/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=69027-64620></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=69028-64619></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/9-592/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>11 Jun 20</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Daniel E. Bauer</strong>, Division of Hematology/Oncology, Boston Children's Hospital, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, USA; Department of Pediatrics, Harvard Medical School, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Yogen Saunthararajah</strong>, Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> YS has patents, owns equity in, and serves on the board of a company EpiDestiny that is developing drug therapy for sickle cell disease. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/9-592/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/9-592/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Drug Therapies for the Management of Sickle...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/9-592/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/9-592/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/9-592/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Rai P and Ataga KI');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/9-592/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/9-592",
            templates : {
                twitter : "Drug Therapies for the Management of Sickle Cell Disease. Rai P and Ataga KI, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/9-592/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Drug Therapies for the Management of Sickle Cell Disease", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Drug Therapies for the Management of Sickle Cell Disease", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/22433/24752")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "24752");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "64619": 1,
                           "64620": 1,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "21f73ff6-f9b7-4924-a80f-c466c65d2e92";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-592.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-592.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-592.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/9-592.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/9-592.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>